var title_f36_35_37424="Ofloxacin: Pediatric drug information";
var content_f36_35_37424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ofloxacin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/55/21363?source=see_link\">",
"       Ofloxacin (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/42/20131?source=see_link\">",
"       Ofloxacin (otic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/28/34246?source=see_link\">",
"       Ofloxacin (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12962 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37424=[""].join("\n");
var outline_f36_35_37424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/55/21363?source=related_link\">",
"      Ofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/42/20131?source=related_link\">",
"      Ofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/28/34246?source=related_link\">",
"      Ofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_35_37425="Hysteroscopic microinsert HSG2";
var content_f36_35_37425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopic sterilization microinsert: Hysterosalpingography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Hysterosalpingogram scout film shows microinsert in expected location.",
"    <br>",
"     (B) During filling phase, contrast fills the uterus but does not extend out to the fallopian tubes.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Deborah Levine, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37425=[""].join("\n");
var outline_f36_35_37425=null;
var title_f36_35_37426="Glomerular disease overview";
var content_f36_35_37426=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Glomerular disease overview (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/35/37426/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37426/contributors\" id=\"au6676\">",
"       Ronald J Falk, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/35/37426/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37426/contributors\" id=\"se49\">",
"       Richard J Glassock, MD, MACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/35/37426/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37426/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/35/37426?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      GLOMERULAR DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Glomerular disease reduces the ability of the kidneys to maintain a balance of certain substances in bloodstream. Normally, the kidneys should filter toxins out of the bloodstream and excrete them in the urine, but should keep red blood cells and protein in the bloodstream. In people with glomerular disease, red blood cells and protein may be excreted into the urine, while toxins may be retained.",
"    </p>",
"    <p>",
"     Glomerular disease can occur by itself (eg, affecting only the kidney), or may be associated with an underlying medical condition that affects other organ systems, such as lupus, diabetes, or certain infections. Glomerular disease can develop suddenly (called acute), or develop slowly over a period of years (called chronic). Treatment of glomerular disease depends upon its cause and type.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      NORMAL KIDNEY FUNCTION",
"     </span>",
"    </p>",
"    <p>",
"     To understand glomerular disease, it may be helpful to understand how the kidneys normally function. The kidneys are bean-shaped, approximately fist-sized organs that are located in the mid-back, just below the rib cage on each side of the body (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_figure graphicRef80336 \" href=\"mobipreview.htm?3/35/3634\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The kidneys filter the body's blood supply with tiny structures, known as nephrons (",
"     <a class=\"graphic graphic_figure graphicRef82497 \" href=\"mobipreview.htm?5/10/5286\">",
"      figure 3",
"     </a>",
"     ). Each nephron is composed of a glomerulus and a tubule. The glomerulus filters wastes and excess fluids, while the tubules modify the waste to form urine. Glomerular disease affects the glomerulus, causing it to filter and excrete incorrectly.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      GLOMERULAR DISEASE FEATURES",
"     </span>",
"    </p>",
"    <p>",
"     Signs and symptoms of glomerular disease depend upon the cause. The first sign of a problem may be an abnormal urine test (urinalysis) that was performed for other reasons.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The urinalysis may show red blood cells, which normally should not be present.",
"      </li>",
"      <li>",
"       The urine may be discolored; red blood cells in the urine can cause the urine to become a light or dark brown color (called hematuria). (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"        \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Excessive protein in the urine (called proteinuria) can cause the urine to appear foamy in the toilet. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=see_link\">",
"        \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Signs and symptoms may also include an elevated blood pressure (greater than",
"     <span class=\"nowrap\">",
"      140/90",
"     </span>",
"     mmHg), fluid retention (edema) in the hands, face, feet,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     abdomen, fatigue (due to anemia or kidney failure), or urinating infrequently. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"      \"Patient information: Edema (swelling) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TYPES OF GLOMERULAR DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     The three basic types of glomerular disease include: focal nephritic, diffuse nephritic, and nephrotic. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"      \"Differential diagnosis and evaluation of glomerular disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Focal nephritic",
"     </span>",
"     &nbsp;&mdash;&nbsp;The key feature of focal nephritic disease is blood in the urine (hematuria) without significant impairment of kidney function or proteinuria. A person with focal glomerulonephritis may not have any symptoms and their condition may go unnoticed until blood and protein are found during a routine urinalysis.",
"    </p>",
"    <p>",
"     The following conditions may cause focal glomerulonephritis.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Less than 15 years old &ndash; Mild postinfectious glomerulonephritis, IgA nephropathy, thin basement membrane disease, hereditary nephritis, Henoch-Sch&ouml;nlein purpura, mesangial proliferative glomerulonephritis",
"      </li>",
"      <li>",
"       15 to 40 years old &ndash; IgA nephropathy, thin basement membrane disease, lupus, hereditary nephritis, mesangial proliferative glomerulonephritis",
"      </li>",
"      <li>",
"       Greater than 40 years old &ndash; IgA nephropathy",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Diffuse nephritic",
"     </span>",
"     &nbsp;&mdash;&nbsp;Persons with diffuse nephritic disease have hematuria with impaired kidney function and proteinuria. This may be a severe form of focal nephritic disease for some people, or may be caused by a bodywide disease. Urinalysis may also show high levels of protein, and patients may have edema (swelling in the lower legs) or high blood pressure.",
"    </p>",
"    <p>",
"     The following conditions may cause diffuse glomerulonephritis.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Less than 15 years old &ndash; Postinfectious glomerulonephritis, membranoproliferative glomerulonephritis",
"      </li>",
"      <li>",
"       15 to 40 years old &ndash; Postinfectious glomerulonephritis, lupus, rapidly progressive glomerulonephritis, fibrillary glomerulonephritis, membranoproliferative glomerulonephritis",
"      </li>",
"      <li>",
"       Greater than 40 years old &ndash; Rapidly progressive glomerulonephritis, vasculitis (including mixed cryoglobulinemia), fibrillary glomerulonephritis, postinfectious glomerulonephritis",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Nephrotic syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with nephrotic syndrome generally have protein in the urine (proteinuria) but little to no blood in the urine (hematuria). Kidney function may worsen as nephrotic syndrome progresses. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/2/35875?source=see_link\">",
"      \"Patient information: The nephrotic syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The following conditions may cause nephrotic syndrome.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Less than 15 years old &ndash; Minimal change disease, focal segmental glomerulosclerosis, mesangial proliferative glomerulonephritis",
"      </li>",
"      <li>",
"       15 to 40 years old &ndash; Focal segmental glomerulosclerosis, minimal change disease, membranous nephropathy (including lupus), diabetic nephropathy, preeclampsia, postinfectious glomerulonephritis (later stage)",
"      </li>",
"      <li>",
"       Greater than 40 years old &ndash; Focal segmental glomerulosclerosis, membranous nephropathy, diabetic nephropathy, minimal change disease, IgA nephropathy, primary amyloidosis or the related disorder light chain deposition disease (which can account for 15 to 20 percent of cases in patients over the age of 60), benign nephrosclerosis (often due to high blood pressure), postinfectious glomerulonephritis (later stage)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      GLOMERULAR DISEASE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Glomerular disease is diagnosed based upon blood or urine tests. Other tests, including imaging tests",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a kidney biopsy, may be used to help diagnose the specific type of glomerular disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Urine tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;The urinalysis may show red blood cells (which are seen when there is damage or inflammation in the glomeruli), white blood cells (which can indicate inflammation), or increased protein levels (which is an indicator of glomerular damage).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests are used to measure the level of creatinine and blood urea nitrogen (BUN), which become elevated when the kidneys are damaged and are not filtering properly. Blood tests may also be used to diagnose underlying medical conditions (such as diabetes, lupus, or certain infections).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;An ultrasound of the kidney is frequently recommended if glomerular disease is suspected, primarily to rule out other causes of blood in the urine",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     decreased kidney function. The ultrasound can also measure the size of the kidneys, which can provide a clue as to the duration of the kidney disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Kidney biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A kidney (renal) biopsy may be needed to definitively determine the cause of glomerular disease in patients that cannot be diagnosed by blood tests or imaging tests alone. A separate topic review discusses renal biopsy. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/14/30944?source=see_link\">",
"      \"Patient information: Renal (kidney) biopsy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      GLOMERULAR DISEASE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of glomerular disease depends upon the form (acute or chronic), the underlying cause, and the severity of associated signs and symptoms. Some forms of glomerular disease, such as that caused by infection, improve after the infection is treated.",
"    </p>",
"    <p>",
"     Other types of glomerular disease may require treatment with immune suppressant medications, such as glucocorticoids (commonly called steroids). Rapidly progressive glomerulonephritis is sometimes treated with plasmapheresis, which removes components of the blood that could be causing the inflammation. Some forms of glomerular disease do not require treatment, while others do not respond to any therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Manging high blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Management of high blood pressure is important to prevent further damage to the kidneys; one or more medications may be needed. One or more high blood pressure medications may be recommended for patients with chronic glomerular disease to decrease the amount of protein in the urine and slow the rate of progression of kidney disease. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"      \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      GLOMERULAR DISEASE COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Some types of glomerular disease are associated with complications, including high blood pressure, acute or chronic kidney failure, and nephrotic syndrome. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/2/35875?source=see_link\">",
"      \"Patient information: The nephrotic syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      High blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;High blood pressure can develop in people with glomerular disease due to kidney damage and build up of waste products and excess fluid in the bloodstream. One or more medications may be needed to reduce blood pressure and prevent further damage to the kidneys. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Acute kidney failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sudden onset (acute) kidney failure is more likely to occur with acute glomerulonephritis (eg, diffuse nephritic). If the glomeruli are unable to filter the blood adequately, waste products and excess fluids build up in the bloodstream quickly. Hemodialysis may be needed to remove waste products and excess fluids. This could be temporary, until the kidney function recovers, or may be long-term if the kidneys become damaged. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"      \"Patient information: Hemodialysis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Chronic kidney failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;If kidney function continues to worsen, dialysis or kidney transplantation may be needed to perform the normal functions of the kidneys. There are two types of dialysis: hemodialysis and peritoneal dialysis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"      \"Patient information: Hemodialysis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/10/14501?source=see_link\">",
"      \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112942814\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H438027\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/31/37363?source=see_link\">",
"      Patient information: Glomerular disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/37/16978?source=see_link\">",
"      Patient information: Cadmium toxicity (Cadmium poisoning) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/59/12211?source=see_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H438034\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=see_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/2/35875?source=see_link\">",
"      Patient information: The nephrotic syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/14/30944?source=see_link\">",
"      Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/10/14501?source=see_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112942800\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=see_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40261?source=see_link\">",
"      Pathogenesis of tissue injury in glomerulonephritis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Kidney Fund",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.akfinc.org/\">",
"      www.akfinc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Association of Kidney Patients",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aakp.org/\">",
"      www.aakp.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/35/37426?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_35_37426=[""].join("\n");
var outline_f36_35_37426=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           GLOMERULAR DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           NORMAL KIDNEY FUNCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           GLOMERULAR DISEASE FEATURES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TYPES OF GLOMERULAR DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           GLOMERULAR DISEASE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           GLOMERULAR DISEASE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           GLOMERULAR DISEASE COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\" title=\"figure 1\">",
"           Urinary tract anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/35/3634\" title=\"figure 2\">",
"           Kidney anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/10/5286\" title=\"figure 3\">",
"           Nephron anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_35_37427="Arthrogram full thickness cuff tear MR";
var content_f36_35_37427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Full thickness rotator cuff tear on magnetic resonance imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance imaging of the right shoulder utilizing fat suppressed T1 weighting and intraarticular injection of gadolinium (MR arthrography). In the oblique coronal view (upper panel), there is contrast within the distal supraspinatus tendon, indicative of a tear (arrow). In the axial view (lower panel), contrast has traveled through the tear into the subdeltoid bursa (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas H Brown, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37427=[""].join("\n");
var outline_f36_35_37427=null;
var title_f36_35_37428="Atopic dermatitis infant 2";
var content_f36_35_37428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis - infantile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented patches are present on the face of this infant with atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37428=[""].join("\n");
var outline_f36_35_37428=null;
var title_f36_35_37429="Heart attack medicines PI";
var content_f36_35_37429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    How medicines help prevent heart attacks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In people with coronary heart disease, fatty deposits called plaques form inside the arteries that supply the heart with blood. Most heart attacks happen when these plaques break open or rupture. If a plaque ruptures, blood clots form around the rupture point, blocking the flow of blood to the heart muscle. The medicines that help prevent heart attack work on different parts of this process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37429=[""].join("\n");
var outline_f36_35_37429=null;
var title_f36_35_37430="Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)";
var content_f36_35_37430=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37430/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37430/contributors\">",
"     Anna Nowak-W��grzyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37430/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37430/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37430/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37430/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/35/37430/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral allergy syndrome (OAS) describes allergic reactions that occur upon ingestion of certain fresh fruits, nuts, vegetables, or spices in pollen-sensitized individuals. The symptoms result from contact urticaria of the mucosal surface that contacts the food. Symptoms are usually limited to the mouth and throat and observed with raw forms of the food, because the responsible allergens are rapidly inactivated by digestion and cooking, although this is not uniformly true. Systemic reactions are observed in 2 to 10 percent of patients, and reactions to cooked plant foods (including roasted nuts) are possible.",
"   </p>",
"   <p>",
"    In this topic review, the term OAS is used to describe reactions limited to the oropharynx. Pollen-food allergy syndrome or pollen-associated food allergy syndrome (PFAS) is a broader term that encompasses both oropharyngeal and systemic symptoms and is the preferred term for the spectrum of reactions caused by allergens in plant foods that are homologous to pollen allergens.",
"   </p>",
"   <p>",
"    This topic review presents the management and prognosis of patients with PFAS. The clinical manifestations, diagnosis, and pathogenesis of PFAS are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=see_link\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach presented in this topic review is based upon the author's practice experience, because there are no established guidelines for the management of PFAS and clinicians vary considerably in their practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study specifically addressed the diagnosis and management of PFAS by allergists across the United States, using a questionnaire mailed to 226 randomly-selected specialists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/1\">",
"     1",
"    </a>",
"    ]. Responses were returned by 122 allergists and revealed an array of practices. Median estimates of the prevalence of OAS in patients with pollen allergy were 5 percent among children and 8 percent among adults, which is significantly lower than the prevalence reported in published series, suggesting underdiagnosis. Fifty-three percent of allergists recommended complete avoidance of causal foods to all patients, whereas 9 percent did not advocate any restrictions. Three percent always prescribed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    for OAS, 30 percent never did, and 66 percent did so on a case by case basis. (See",
"    <a class=\"local\" href=\"#H1929291\">",
"     'Indications for epinephrine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Food avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analogous to other forms of food allergy, dietary avoidance of the offending food(s) is the mainstay of the management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should avoid the specific raw fruits or vegetables or the nuts (roasted or raw) that have caused symptoms in the past.",
"     </li>",
"     <li>",
"      Patients should be made aware that dehydrated forms of the food may be used in seasonings and can cause reactions (eg, patients allergic to raw celery may react to celery spice, which is dried and powdered celery) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The purpose of avoidance is the prevention of future reactions; there are no studies reporting the impact of avoidance on the natural history of the condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1929141\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION ABOUT RISK OF SYSTEMIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of how best to counsel patients with PFAS about the risk of a future systemic reaction is controversial. Our approach is to inform patients and caregivers about the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of multiple studies, which included over 1000 patients, estimated that between 2 and 10 percent of patients with PFAS experience systemic symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/5\">",
"       5",
"      </a>",
"      ]. This is discussed elsewhere (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Systemic reactions'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Systemic reactions to previously tolerated foods can occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although rare, systemic reactions to first ingestions of pollen-related foods have been reported. Specifically, severe reactions upon the first ingestion of a soy beverage with high concentration of birch cross-reactive proteins was described in a group of children during the birch pollen season [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1929291\">",
"    <span class=\"h2\">",
"     Indications for epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a systemic reaction among patients with PFAS is estimated at 2 to 10 percent, as discussed previously. Practices regarding prescribing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    vary among allergists, so our approach is presented here. We advise patients with one or more of the following characteristics to carry epinephrine autoinjectors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic symptoms in the past.",
"     </li>",
"     <li>",
"      Reactions of any severity to",
"      <strong>",
"       cooked",
"      </strong>",
"      plant foods.",
"     </li>",
"     <li>",
"      Established allergy (regardless of the severity of past reactions) to peanut, tree nuts, or mustard, as these foods are associated with higher rates of systemic reactions.",
"     </li>",
"     <li>",
"      Reactions to particular foods, if practicing in an area where that food is associated with severe reactions, such as peach or apple in Mediterranean countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. The phenomenon of certain foods causing more severe reactions in patients in specific geographical locales is discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=see_link\">",
"       \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharyngeal anatomy that may predispose to severe obstruction even with mild degree of swelling such as large tonsillar tissue or large tongue.",
"     </li>",
"     <li>",
"      Patients who have reported dysphagia or significant throat discomfort during the past reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients positive SPT using a commercial extract, we discuss with the patient or parent the unknown natural history of this condition and the uncertain risk of systemic reactions. If the",
"    <span class=\"nowrap\">",
"     patient/parent's",
"    </span>",
"    preference is to have access to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    following that discussion, then we generally supply it. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Food avoidance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SPECIFIC CLINICAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues that often arise with specific patient presentations are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients with isolated oropharyngeal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of PFAS with isolated oropharyngeal symptoms, we usually do not pursue testing for sensitization to and prophylactic avoidance of potentially cross-reactive foods. The patient may be given a printed list of related foods and advised to avoid the raw forms of any that cause symptoms (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"mobipreview.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ). Anecdotally, some patients choose to continue ingesting fruits that are causing mild oral symptoms. Such patients should be advised to avoid eating large amounts of the food, such as in a fruit-shake or during apple picking. The symptoms may worsen during or following the pollen season and food should be avoided during such periods.",
"   </p>",
"   <p>",
"    We suggest that patients who are able to tolerate fruits and vegetables that have been cooked or otherwise thermally processed (microwaved, pasteurized, or baked) continue to eat these forms of the food. When making this recommendation, however, the clinician must be certain that patients are not experiencing other types of reactions to the plant-foods in question. As an example, adult patients with concomitant OAS and atopic dermatitis can have eczematous reactions to fruits and vegetables, even after cooking:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, double-blind, placebo-controlled food challenges were performed with cooked apple, carrot, or celery, in patients with atopic dermatitis and birch pollen allergy, who experienced OAS and skin symptoms upon ingestion of the foods in raw form. Cooked versions of the culprit foods did not cause OAS, although they did cause worsening of eczema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study showed that heating and digestion abolished the IgE binding ability of Bet v 1 cross-reactive food allergens in apple, celery, carrot; however, there was no effect on the T cell binding epitopes of those allergens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Thus, T-cell mediated mechanisms may have been responsible for the worsening of atopic dermatitis observed in some patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1929719\">",
"    <span class=\"h2\">",
"     Patients with oral allergy to high-risk foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanut, tree nuts, and mustard are associated with higher rates of systemic reactions, as mentioned above. In addition, peach is associated with systemic reactions in the Mediterranean region, due to the LTP sensitization. The rates of systemic reactions to peach in other regions of the world are not known but are likely lower than in the Mediterranean region. We recommend that all patients with established allergies to these foods, regardless of the severity of past symptoms, learn to use and carry an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjector. (See",
"    <a class=\"local\" href=\"#H1929291\">",
"     'Indications for epinephrine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Advice regarding avoidance for patients who have had very mild oropharyngeal symptoms to one of these foods is a difficult issue, especially if the individual wishes to continue eating cooked forms of the food that are not currently causing symptoms. We typically explain to the patient that the culprit food is more likely to cause dangerous reactions, compared to other foods, and suggest that they convert to strict avoidance if the symptoms seem to be progressing over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Patients with systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PFAS who have experienced systemic reactions to a raw food should avoid raw and dehydrated forms of that food. The decision to avoid cooked versions of the culprit food as well is influenced by the severity of the patient's reaction and the patient's recent history of tolerating cooked versions, as well as the preferences of the patient and clinician. This decision is usually made on a case by case basis.",
"   </p>",
"   <p>",
"    Tolerance to cross-reactive foods should be carefully evaluated in any patient who has experienced systemic symptoms, so that the foods that must be avoided are clearly defined. If a cross-reactive food is being ingested on regular basis without adverse symptoms, it is not necessary to test or restrict that food. In contrast, if the cross-reactive food is not a usual part of the diet, a clinician-supervised oral food challenge may be needed to determine tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHER MANAGEMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Caution with anti-ulcer treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-ulcer drugs increase gastric pH and may impair digestion of food proteins. There are no published studies directly examining the clinical effect of anti-ulcer therapies on PFAS, although the results of studies of other food allergies are of interest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a mouse model, anti-ulcer drugs were reported to predispose to allergic reactions to caviar caused by unstable allergens that would be normally destroyed by digestion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Following a three month course of anti-ulcer drugs, 5 of 153 patients developed IgE to hazelnut and 2 developed clinical allergy to hazelnut [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/14\">",
"       14",
"      </a>",
"      ]. In addition, 10 percent of the patients showed a boost of pre-existing IgE antibodies and 15 percent de novo IgE formation toward numerous digestion-labile dietary compounds, like milk, potato, celery, carrots, apple, orange, wheat, and rye flour [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations, although preliminary, suggest that patients with PFAS may be at risk for more severe reactions while being treated with anti-ulcer drugs and should practice more careful food avoidance if these medications are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Therapies of uncertain benefit",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest premedicating with antihistamines in order to eat the",
"    <span class=\"nowrap\">",
"     fruit/vegetable",
"    </span>",
"    in question. However, there is some evidence that antihistamines can reduce the symptoms of OAS. In a randomized, placebo-controlled clinical trial, patients with birch allergy and hazelnut OAS who received a two week course of the H1-receptor antagonist, astemizole, had significantly reduced symptoms on oral challenge compared with placebo; although symptoms did not resolve completely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/16\">",
"     16",
"    </a>",
"    ]. Still, the longer-term effects of continuing to eat a food that causes OAS have not been evaluated. We prefer instead to advise patients to eat only cooked or processed forms of the food that do not cause symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Immunotherapy for pollen allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy (IT) for treatment of pollen allergy (both injected and oral forms) appears to benefit a subset of patients with OAS. Randomized clinical trials of birch pollen immunotherapy in subjects with apple allergy suggest that a subset of birch allergic patients with apple allergy experience a decrease in OAS symptoms in about 60 to 80 percent of the treated patients, ranging from increased tolerance of raw apple to complete resolution of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. However, some patients experience no change in their OAS symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The favorable response to",
"      <strong>",
"       subcutaneous",
"      </strong>",
"      IT is associated with decreased skin prick test to raw apple, but no decrease in serum apple-IgE levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. Following discontinuation of IT, skin test reactivity to apple gradually increases, although about 50 percent of patients who benefited from IT in one study, still tolerated raw apple more than two years after discontinuation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/19\">",
"       19",
"      </a>",
"      ]. One group of investigators has suggested that immunotherapy might work best for OAS in adults mono-sensitized to birch tree pollen and not to multiple pollens and in those treated with birch pollen extracts containing relatively high doses of Bet v1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a trial of",
"      <strong>",
"       sublingual",
"      </strong>",
"      immunotherapy for birch pollen allergy did not show efficacy for alleviating PFAS symptoms, however this study used a very low maintenance dose of Bet v 1 (4.5 &micro;g) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small study comparing injection and oral forms of immunotherapy for OAS, complete tolerance to raw apple was achieved in two of 8 and one of seven patients receiving injection and oral IT, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37430/abstract/24\">",
"       24",
"      </a>",
"      ]. An additional three in the injection group and two in the oral group tolerated increased doses of raw apple.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach is not to recommend pollen IT solely for the purpose of treating PFAS, although we would consider it if the patient is very troubled by the symptoms and understands that immunotherapy only works in a subset of individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Anti-IgE therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no information regarding PFAS in patients receiving anti-IgE therapy for allergic rhinitis or asthma has been published to date, it appears to be an attractive potential approach in view of the central role of IgE-reactions in the pathomechanism of PFAS. However, clinical trials are necessary to evaluate the role of anti-IgE therapy for treatment of PFAS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26942651\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies on the long-term natural history and prognosis of PFAS are lacking. In our experience, PFAS is usually a persistent condition. Little data are available about long-term outcomes in patients who respond to pollen immunotherapy initially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral allergy syndrome (OAS) and pollen-food allergy syndrome (PFAS) are IgE-mediated allergic reactions that occur upon ingestion of certain fresh fruits, nuts, vegetables, or spices in pollen-sensitized individuals. The symptoms result from contact urticaria of the mucosal surface that touches the food and are caused by allergens in plant foods that are homologous to pollen allergens (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"mobipreview.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with PFAS should be informed of the small, but definite risk for systemic reactions and the possibility of reacting to related foods upon first exposure. We also provide patients with a printed diagram of related foods that might also be expected to cause symptoms (",
"      <a class=\"graphic graphic_figure graphicRef60787 \" href=\"mobipreview.htm?16/1/16409\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Food avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term consequences of continuing to ingest raw foods that cause PFAS are unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who are significantly bothered by PFAS symptoms limited to the oropharynx typically want to avoid the raw foods that cause symptoms.",
"     </li>",
"     <li>",
"      For patients who wish to continue eating foods that cause mild symptoms limited to the oropharynx, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      restricting food intake (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Food avoidance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Patients with isolated oropharyngeal reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic reactions occur in 2 to 10 percent of patients. Patients with PFAS who experienced systemic symptoms in the past should carry",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjectors. (See",
"      <a class=\"local\" href=\"#H1929291\">",
"       'Indications for epinephrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PFAS and systemic symptoms must avoid the raw form of the responsible food. We suggest that such patients also avoid cooked forms of the responsible food (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Exceptions to this may be patients who have recently tolerated cooked forms of the food, whose systemic symptoms to raw food were not life-threatening, and who strongly desire to continue eating cooked forms.",
"     </li>",
"     <li>",
"      If a patient wishes to continue eating cross-reactive foods, we evaluate for allergy to the foods in question, so that the foods that must be avoided are clearly defined. If the patient wishes to continue eating other foods to which they test positive, but have not eaten recently, then we perform a clinician-supervised oral food challenge to determine tolerance. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Patients with systemic reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients who have not experienced systemic reactions carry",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjectors if any of the following are true (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H1929291\">",
"       'Indications for epinephrine'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Allergy to peanut, tree nuts, or mustard has been objectively established",
"     </li>",
"     <li>",
"      The patient experienced an oropharyngeal reaction to a cooked plant food.",
"     </li>",
"     <li>",
"      The patient had a positive SPT to a commercial extract for the culprit food.",
"     </li>",
"     <li>",
"      The patient reacted to a food that is associated with higher rates of systemic reaction in the geographical area in question (eg, a patient with allergy to apple living in Spain).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapies of uncertain benefit for PFAS include prophylactic administration of H1-antihistamines, pollen immunotherapy, and anti-IgE therapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Other management issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/1\">",
"      Ma S, Sicherer SH, Nowak-Wegrzyn A. A survey on the management of pollen-food allergy syndrome in allergy practices. J Allergy Clin Immunol 2003; 112:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/2\">",
"      Blein JP, Coutos-Th&eacute;venot P, Marion D, Ponchet M. From elicitins to lipid-transfer proteins: a new insight in cell signalling involved in plant defence mechanisms. Trends Plant Sci 2002; 7:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/3\">",
"      Mari A, Ballmer-Weber BK, Vieths S. The oral allergy syndrome: improved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol 2005; 5:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/4\">",
"      Ballmer-Weber BK, Hoffmann A, W&uuml;thrich B, et al. Influence of food processing on the allergenicity of celery: DBPCFC with celery spice and cooked celery in patients with celery allergy. Allergy 2002; 57:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/5\">",
"      Ortolani C, Pastorello EA, Farioli L, et al. IgE-mediated allergy from vegetable allergens. Ann Allergy 1993; 71:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/6\">",
"      Vila L, S&aacute;nchez G, Sanz ML, et al. Study of a case of hypersensitivity to lettuce (Lactuca sativa). Clin Exp Allergy 1998; 28:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/7\">",
"      Kosma P, Sj&ouml;lander S, Landgren E, et al. Severe reactions after the intake of soy drink in birch pollen-allergic children sensitized to Gly m 4. Acta Paediatr 2011; 100:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/8\">",
"      Cuesta-Herranz J, L&aacute;zaro M, Figueredo E, et al. Allergy to plant-derived fresh foods in a birch- and ragweed-free area. Clin Exp Allergy 2000; 30:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/9\">",
"      D&iacute;az-Perales A, Lombardero M, S&aacute;nchez-Monge R, et al. Lipid-transfer proteins as potential plant panallergens: cross-reactivity among proteins of Artemisia pollen, Castanea nut and Rosaceae fruits, with different IgE-binding capacities. Clin Exp Allergy 2000; 30:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/10\">",
"      Fern&aacute;ndez-Rivas M, Bolhaar S, Gonz&aacute;lez-Mancebo E, et al. Apple allergy across Europe: how allergen sensitization profiles determine the clinical expression of allergies to plant foods. J Allergy Clin Immunol 2006; 118:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/11\">",
"      Bohle B, Zw&ouml;lfer B, Heratizadeh A, et al. Cooking birch pollen-related food: divergent consequences for IgE- and T cell-mediated reactivity in vitro and in vivo. J Allergy Clin Immunol 2006; 118:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/12\">",
"      Schimek EM, Zw&ouml;lfer B, Briza P, et al. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing, but not T cell-activating, capacity. J Allergy Clin Immunol 2005; 116:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/13\">",
"      Untersmayr E, Sch&ouml;ll I, Swoboda I, et al. Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice. J Allergy Clin Immunol 2003; 112:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/14\">",
"      Sch&ouml;ll I, Untersmayr E, Bakos N, et al. Antiulcer drugs promote oral sensitization and hypersensitivity to hazelnut allergens in BALB/c mice and humans. Am J Clin Nutr 2005; 81:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/15\">",
"      Untersmayr E, Bakos N, Sch&ouml;ll I, et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J 2005; 19:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/16\">",
"      Bindslev-Jensen C, Vibits A, Stahl Skov P, Weeke B. Oral allergy syndrome: the effect of astemizole. Allergy 1991; 46:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/17\">",
"      Bolhaar ST, Tiemessen MM, Zuidmeer L, et al. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004; 34:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/18\">",
"      Asero R. Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 1998; 28:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/19\">",
"      Asero R. How long does the effect of birch pollen injection SIT on apple allergy last? Allergy 2003; 58:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/20\">",
"      Bucher X, Pichler WJ, Dahinden CA, Helbling A. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004; 59:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/21\">",
"      Hansen KS, Khinchi MS, Skov PS, et al. Food allergy to apple and specific immunotherapy with birch pollen. Mol Nutr Food Res 2004; 48:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/22\">",
"      Asero R. Effects of birch pollen SIT on apple allergy: a matter of dosage? Allergy 2004; 59:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/23\">",
"      Kinaciyan T, Jahn-Schmid B, Radakovics A, et al. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 2007; 119:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37430/abstract/24\">",
"      Mauro M, Russello M, Incorvaia C, et al. Birch-apple syndrome treated with birch pollen immunotherapy. Int Arch Allergy Immunol 2011; 156:416.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2407 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37430=[""].join("\n");
var outline_f36_35_37430=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Food avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1929141\">",
"      PATIENT EDUCATION ABOUT RISK OF SYSTEMIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1929291\">",
"      Indications for epinephrine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SPECIFIC CLINICAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients with isolated oropharyngeal reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1929719\">",
"      Patients with oral allergy to high-risk foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Patients with systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHER MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Caution with anti-ulcer treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Therapies of uncertain benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Immunotherapy for pollen allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26942651\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2407|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/1/16409\" title=\"figure 1\">",
"      Food-pollen relationships",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=related_link\">",
"      Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_35_37431="M mycetomatis skin biopsy";
var content_f36_35_37431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    <em>",
"     Madurella mycetomatis",
"    </em>",
"    skin biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin biopsy demonstrating two grains of",
"    <em>",
"     Madurella mycetomatis",
"    </em>",
"    surrounded by granulomatous reaction (Hematoxylin-Eosin stain x400).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beatriz Bustamante, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37431=[""].join("\n");
var outline_f36_35_37431=null;
var title_f36_35_37432="Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children";
var content_f36_35_37432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37432/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37432/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37432/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37432/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/35/37432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome is caused by renal diseases that increase the permeability across the glomerular filtration barrier. It is classically characterized by four clinical features, but the first two are used diagnostically because the last two may not be seen in all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nephrotic range proteinuria &mdash; Urinary protein excretion greater than 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Hypoalbuminemia &mdash; Serum albumin concentration less than 3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      Edema",
"     </li>",
"     <li>",
"      Hyperlipidemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children are reviewed here. The complications and treatment of idiopathic childhood nephrotic syndrome and specific renal diseases that present as nephrotic syndrome in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=see_link\">",
"     \"Complications of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two issues are important in the pathogenesis of nephrotic syndrome: the mechanisms of glomerular injury and proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms of glomerular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of different, disease-specific mechanisms have been described in the nephrotic syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulating factors in minimal change disease and primary focal segmental glomerulosclerosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Idiopathic nephrotic syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Circulating immune factors in disorders, such as membranoproliferative glomerulonephritis, poststreptococcal glomerulonephritis, and lupus nephritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=see_link\">",
"       \"Mechanisms of immune injury of the glomerulus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mutations in podocyte or slit diaphragm proteins (eg, CD2AP, podocin, and nephrin) in inherited forms of congenital, infantile, or glucocorticoid resistant nephrotic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link\">",
"       \"Congenital and infantile nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21354?source=see_link&amp;anchor=H631397715#H631397715\">",
"       \"Steroid-resistant idiopathic nephrotic syndrome in children\", section on 'Genetic mutations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanisms of proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of proteinuria in patients with nephrotic syndrome is discussed in detail elsewhere but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link&amp;anchor=H3#H3\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Glomerular proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proteinuria in glomerular disease is due to increased filtration of macromolecules (such as albumin) across the glomerular capillary wall. The latter consists of three components: the fenestrated endothelial cell, the glomerular basement membrane (GBM), and the epithelial cell foot processes. The pores between the foot processes are closed by a thin membrane called the slit diaphragm (",
"    <a class=\"graphic graphic_picture graphicRef72505 \" href=\"mobipreview.htm?13/9/13459\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The filtration of macromolecules across the glomerular capillary wall is normally restricted by two mechanisms: charge-selectivity and size-selectivity. The endothelial cells and the GBM have a net negative charge due to polyanions such as heparan sulfate proteoglycans. This creates a charge barrier to the filtration of large anions such as albumin. In comparison, circulating IgG is predominantly neutral or cationic, and its filtration is not limited by charge.",
"   </p>",
"   <p>",
"    In minimal change disease, the most common cause of nephrotic syndrome in children, there is a loss of anionic charge that is not accompanied by any structural damage or change to the glomerular filtration unit observed by light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef71232 \" href=\"mobipreview.htm?12/20/12617\">",
"     picture 2",
"    </a>",
"    ). However, electron microscopy demonstrates epithelial podocyte effacement (",
"    <a class=\"graphic graphic_picture graphicRef58414 \" href=\"mobipreview.htm?20/6/20584\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The glomerular capillary wall is size-selective, having functional pores of an approximate radius of 40 to 45 &Aring; (the radius of albumin is roughly 36 &Aring;). These pores appear to be located throughout the GBM and across the GBM at the slit diaphragms between the adjacent epithelial cell foot processes. In comparison, the width of the endothelial cell fenestrae is much larger (375 to 400 &Aring;); as a result, the endothelial cell is not part of the size barrier to macromolecule filtration.",
"   </p>",
"   <p>",
"    In glomerular diseases other than minimal change disease, structural injury seen by light microscopy results in an increase in the number of large pores in the GBM (",
"    <a class=\"graphic graphic_figure graphicRef76597 \" href=\"mobipreview.htm?10/9/10399\">",
"     figure 1",
"    </a>",
"    ). This structural damage allows movement of normally restricted proteins of varying sizes (including large neutral proteins, such as IgG) across the filtration barrier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this discussion, children with nephrotic syndrome are classified based upon whether or not there are signs of systemic disease. We use the following classification system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary nephrotic syndrome, which refers to nephrotic syndrome in the absence of an identifiable systemic disease. Within this category are patients with idiopathic nephrotic syndrome, who have no glomerular inflammation on renal biopsy, and patients with primary glomerulonephritis, who have an active sediment and glomerular inflammation on renal biopsy.",
"     </li>",
"     <li>",
"      Secondary nephrotic syndrome, which refers to nephrotic syndrome in the presence of an identifiable systemic disease.",
"     </li>",
"     <li>",
"      Congenital and infantile nephrotic syndrome, which occur in children less than one year of age and can be either secondary (mostly due to infection) or primary. Two-thirds of nephrotic syndrome cases that occur during the first year of life and as many as 85 percent of cases that occur during the first three months of life have a genetic basis and a poor outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/1\">",
"       1",
"      </a>",
"      ]. These disorders are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link\">",
"       \"Congenital and infantile nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary nephrotic syndrome is defined as nephrotic syndrome in the absence of systemic disease with a reported incidence of 1.5 per 100,000 children per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/2\">",
"     2",
"    </a>",
"    ]. Within this category are two subgroups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders without glomerular inflammation on renal biopsy. Included in this group are idiopathic nephrotic syndrome and some cases of membranous nephropathy, which are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"       \"Causes and diagnosis of membranous nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephritic disorders associated with an active urine sediment (red cells and cellular casts) and the presence of glomerular inflammation on renal biopsy. Included in this group are membranoproliferative glomerulonephritis and IgA nephropathy, which are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=see_link\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11238?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of a child with glomerular disease\", section on 'Glomerulonephritis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Idiopathic nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic nephrotic syndrome is the most common form of childhood nephrotic syndrome, representing more than 90 percent of cases between 1 and 10 years of age and 50 percent after 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ]. Idiopathic nephrotic syndrome is defined by the association of the clinical features of nephrotic syndrome with renal biopsy findings of diffuse foot process effacement on electron microscopy and minimal changes (called minimal change disease [MCD]), primary focal segmental glomerulosclerosis (FSGS), or mesangial proliferation on light microscopy. It is unclear whether these three light microscopic patterns represent separate disorders or are a spectrum of a single disease process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41717?source=see_link\">",
"     \"Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients have histologic findings of MCD. The vast majority of patients with MCD (&gt;90 percent) respond to steroid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MCD can be clinically differentiated from those with other causes of nephrotic syndrome. This was illustrated in a classic study from the International Study of Kidney Disease in Children (ISKDC) of 521 children (age range 12 weeks to 16 years of age) who presented with primary nephrotic syndrome. The study was conducted in 24 centers in North America, Europe, and Asia between 1967 and 1974 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ]. Renal biopsies were obtained in all children.",
"   </p>",
"   <p>",
"    Multivariate analysis demonstrated that clinical findings at presentation accurately differentiated children with MCD from those with other glomerular pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ]. These findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age younger than six years of age",
"     </li>",
"     <li>",
"      Absence of hypertension",
"     </li>",
"     <li>",
"      Absence of hematuria by Addis count",
"     </li>",
"     <li>",
"      Normal complement levels",
"     </li>",
"     <li>",
"      Normal renal function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One exception to the age criterion is onset of nephrotic syndrome in the first year of life, particularly the first three months of life, which is much more likely to be due to a gene mutation and to be resistant to glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, an initial trial of steroid therapy is generally administered to children who are likely to have MCD based upon clinical diagnosis, thereby avoiding renal biopsy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Initial therapy versus renal biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with idiopathic nephrotic syndrome are further classified based upon their response to empiric steroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steroid-responsive nephrotic syndrome &mdash; The majority of children with idiopathic nephrotic syndrome are steroid-responsive (also referred to as steroid-sensitive nephrotic syndrome). In these patients, the most likely histologic lesion is MCD, although some patients with FSGS will also respond to steroid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients who are steroid-responsive have a favorable long-term outcome with a very low risk of chronic renal disease.",
"     </li>",
"     <li>",
"      Steroid-resistant nephrotic syndrome &mdash; Approximately 20 percent of all children with idiopathic nephrotic syndrome will not respond to steroid therapy. The response rate is better in younger children, who are much more likely to have MCD. In an ISKDC study, only about 10 percent of children less than 10 years of age failed to respond to steroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients with steroid resistant nephrotic syndrome have a worse prognosis as renal survival rate in Caucasian children is approximately 50 percent at 10 years and even worse in children with African or Hispanic ethnicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some children with steroid-resistant nephrotic syndrome have genetic mutations of podocyte proteins, including",
"      <em>",
"       NPHS2",
"      </em>",
"      ,",
"      <em>",
"       NPHS1",
"      </em>",
"      , and",
"      <em>",
"       WT1",
"      </em>",
"      genes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21354?source=see_link&amp;anchor=H631397715#H631397715\">",
"       \"Steroid-resistant idiopathic nephrotic syndrome in children\", section on 'Genetic mutations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Secondary nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary nephrotic syndrome is defined as nephrotic syndrome associated with systemic diseases or is secondary to another process that causes glomerular injury. Within this category are the same two subgroups as in primary nephrotic syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders without glomerular inflammation on renal biopsy. Included in this group are some cases of membranous nephropathy (eg, due to lupus,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/26/6566?source=see_link\">",
"       penicillamine",
"      </a>",
"      ), secondary focal segmental glomerulosclerosis due to nephron loss resulting from renal scarring or hypoplasia, and, rarely, disorders such as amyloidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"       \"Causes and diagnosis of membranous nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephritic disorders associated with an active urine sediment (red cells and cellular casts) and the presence of glomerular inflammation on renal biopsy. A variety of disorders are included in this group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Postinfectious glomerulonephritis and infective endocarditis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=see_link\">",
"       \"Poststreptococcal glomerulonephritis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5556?source=see_link\">",
"       \"Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vasculitides, such as Henoch-Sch&ouml;nlein purpura (IgA vasculitis), and, rarely, in granulomatosis with polyangiitis (formerly referred to as Wegener&rsquo;s granulomatosis) and microscopic polyangiitis. (See",
"      <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link\">",
"       \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes include sickle cell disease, which is usually associated with secondary focal segmental glomerulosclerosis, Alport syndrome, and hemolytic uremic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link\">",
"       \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal change disease (MCD) is the most commonly seen histopathology of childhood nephrotic syndrome. In the previously mentioned ISKDC study of 521 children who presented with nephrotic syndrome without systemic disease between 1967 and 1974, the following findings were made based upon renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimal change disease (MCD) &mdash; 77 percent",
"     </li>",
"     <li>",
"      Membranoproliferative glomerulonephritis (MPGN) &mdash; 8 percent",
"     </li>",
"     <li>",
"      Focal segmental glomerulosclerosis (FSGS) &mdash; 7 percent",
"     </li>",
"     <li>",
"      Proliferative glomerulonephritis &mdash; 2 percent",
"     </li>",
"     <li>",
"      Mesangial proliferation &mdash; 2 percent",
"     </li>",
"     <li>",
"      Focal and global glomerulosclerosis &mdash; 2 percent",
"     </li>",
"     <li>",
"      Membranous glomerulonephropathy &mdash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eighty percent of patients with MCD and 50 percent of patients with FSGS presented before six years of age. In contrast, none of the 39 patients with MPGN presented before six years of age.",
"   </p>",
"   <p>",
"    Subsequent studies have demonstrated an increasing prevalence of FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Whether this is due to a true increase in prevalence or is a result of improved detection of the histologic changes consistent with FSGS on renal biopsy is unknown. Since the diagnosis of FSGS is made by the detection of one or more glomeruli with segmental glomerulosclerosis, one cannot be certain that a patient with an initial diagnosis of MCD does not actually have FSGS that was missed because of sampling error.",
"   </p>",
"   <p>",
"    In addition, advances in molecular genetics of glomerular diseases have shown single gene defects that affect glomerular basement membrane formation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glomerular podocyte differentiation and function are responsible for many cases of steroid-resistant nephrotic syndrome in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21354?source=see_link&amp;anchor=H631397715#H631397715\">",
"     \"Steroid-resistant idiopathic nephrotic syndrome in children\", section on 'Genetic mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary nephrotic syndrome is more common in younger children, particularly those less than six years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/2,3,10\">",
"     2,3,10",
"    </a>",
"    ]. There is an increased incidence of nephrotic syndrome in family members when compared to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In affected siblings, nephrotic syndrome usually presents at the same age with the same histopathology and outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Childhood nephrotic syndrome generally presents with edema and often occurs after an inciting event, such as an upper respiratory infection or an insect bite.",
"   </p>",
"   <p>",
"    Two major factors have been thought to be responsible for edema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium retention directly induced by the renal disease, which is most common.",
"     </li>",
"     <li>",
"      Arterial underfilling as the low plasma oncotic pressure leads to plasma volume depletion and stimulation of the renin-angiotensin-aldosterone system with renal sodium retention under the influence of aldosterone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary sodium retention is a result of increased sodium reabsorption in the collecting duct of the nephrotic kidney due to an uncontrolled activation of the epithelial sodium channels (ENaC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link&amp;anchor=H1#H1\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\", section on 'Underfilling versus renal sodium retention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\", section on 'Varying mechanisms in childhood minimal change disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Edema increases gradually and becomes detectable when fluid retention exceeds 3 to 5 percent of body weight. Typically, periorbital edema is noted first and is often misdiagnosed as a manifestation of allergy. The edema is gravity dependent, and thus, over the day, periorbital edema decreases while edema of the lower extremities increases. In the reclining position, edema localizes to the back and sacral area. Other dependent areas that can become edematous include the scrotum, penis, or labia. The affected edematous areas are white, soft, and pitting.",
"   </p>",
"   <p>",
"    Some patients develop anasarca (ie, generalized and massive edema) with marked peripheral edema, abdominal distension resulting from ascites, marked scrotal or vulvar edema, and severe periorbital edema resulting in swollen shut eyelids.",
"   </p>",
"   <p>",
"    Despite the marked increase in extracellular fluid volume, some children with nephrotic syndrome, primarily those with MCD, present with or develop signs of a decrease in effective circulating volume, such as tachycardia, peripheral vasoconstriction, oliguria, decreased glomerular filtration rate, elevation of plasma renin aldosterone, and norepinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/13\">",
"     13",
"    </a>",
"    ]. In such children, a further insult such as diuretic therapy, sepsis, or diarrhea can lead to hypotension and rarely shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of other manifestations can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=see_link\">",
"     \"Complications of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Umbilical or inguinal hernias.",
"     </li>",
"     <li>",
"      Abdominal pain due to rapid fluid accumulation or peritonitis.",
"     </li>",
"     <li>",
"      Dyspnea, which is most often due to respiratory compromise from pleural effusions or marked ascites. Infrequently, respiratory symptoms may be due to pneumonia or, rarely, pulmonary embolus due to the hypercoagulable state associated with the nephrotic syndrome.",
"     </li>",
"     <li>",
"      Nonspecific complaints, including headache, irritability, malaise, and fatigue are common at presentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood of hypertension varies with the underlying cause of nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ]. Hypertension is common in patients with glomerulosclerosis or glomerulonephritis, but is infrequent in patients with idiopathic nephrotic syndrome.",
"   </p>",
"   <p>",
"    Gross hematuria is most often seen in patients with glomerulonephritis (eg, postinfectious glomerulonephritis or membranoproliferative glomerulonephritis). In contrast, gross hematuria is rare in idiopathic nephrotic syndrome, although microscopic hematuria is seen in 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Urinalysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nephrotic syndrome is made by fulfilling the following two defining characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinary protein excretion greater than 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Hypoalbuminemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although, edema is generally the presenting sign of nephrotic syndrome, the diagnosis is confirmed by the presence of nephrotic range proteinuria and hypoalbuminemia.",
"   </p>",
"   <p>",
"    Clinical and laboratory findings can also be used to diagnosis specific diseases that present as nephrotic syndrome. In particular, clinical findings are highly predictive of idiopathic nephritic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ] and are used to make the diagnosis initiate steroid therapy without renal biopsy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Initial therapy versus renal biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our approach is consistent with the following initial evaluation of nephrotic syndrome developed by the Children's Nephrotic Syndrome Consensus Conference, which included pediatric nephrologists from the southeast and midwest sections of the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      First morning void to measure urinary protein to creatinine ratio",
"     </li>",
"     <li>",
"      Blood tests, including electrolytes, creatinine, blood urea nitrogen, cholesterol, albumin, and C3",
"     </li>",
"     <li>",
"      Other blood tests include antinuclear antibody level for patients &ge; 10 years of age or with signs of systemic lupus erythematosus, and serology for hepatitis B, C, and HIV in high-risk populations",
"     </li>",
"     <li>",
"      Renal biopsy for children &ge;12 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Urine tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Urine protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotic range proteinuria in children is defined as urinary protein excretion greater than 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or 40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per hour. Quantitative measurement of protein excretion is based upon a timed 24-hour urine collection.",
"   </p>",
"   <p>",
"    However, it is difficult to obtain accurately timed urine collections in young children. An alternative method of quantitative assessment of urine protein excretion is measurement of the total",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio on a spot urine sample (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/18/16673?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The ratio that is indicative of nephrotic range proteinuria is greater than 3 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine (300 mg",
"    <span class=\"nowrap\">",
"     protein/mmol",
"    </span>",
"    creatinine). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26262?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of proteinuria in children\", section on 'Quantitative assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary dipstick measures albumin concentration via a colorimetric reaction between albumin and tetrabromophenol blue. It measures protein concentration rather than the rate of protein excretion and, therefore, cannot be used to make the diagnosis of nephrotic syndrome. However, in most patients with nephrotic syndrome, the urinary dipstick demonstrates a high albumin concentration (3+ to 4+, 300 to &gt;1000",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    Thus, it is often used as a screening test while awaiting confirmation by quantitative protein excretion studies.",
"   </p>",
"   <p>",
"    Patients with idiopathic nephrotic syndrome have a relatively inactive urine sediment (ie, oval fat bodies and hyaline casts but few red cells and no red cell or other cellular casts). Hematuria is commonly seen in patients with glomerulonephritis but does occur in focal segmental sclerosis (FSGS) and, less often, minimal change disease (MCD). This was illustrated in the previously mentioned ISKDC study of 521 children who presented with primary nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ]. Hematuria was reported in 59 percent of patients with membranoproliferative glomerulonephritis, 49 percent of those with FSGS, and 23 percent with MCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Serum proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoalbuminemia is one of the criteria that defines nephrotic syndrome. The serum albumin is typically below 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    and can be as low as 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Hypoalbuminemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although serum albumin is reduced, total globulins are relatively preserved in patients with idiopathic nephrotic syndrome with either normal or slightly decreased serum alpha-1 globulin concentrations and increased alpha-2 and beta globulin. Gamma globulin concentrations vary depending upon the underlying disease. As examples, serum IgG is reduced in patients with MCD and is elevated in those with systemic lupus erythematous (SLE).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia is a characteristic feature of nephrotic syndrome. Serum total cholesterol, triglycerides, and total lipids are elevated. The increase in cholesterol is inversely correlated to the serum albumin concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Estimation of GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In stable patients, the glomerular filtration rate (GFR) is estimated from the serum creatinine. The serum creatinine is elevated in 30 to 40 percent of patients with MCD at presentation, due at least in part to hypovolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3,13\">",
"     3,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count &mdash; Hemoglobin and hematocrit may be increased in children with nephrotic syndrome, particularly MCD, as a result of plasma volume contraction. Thrombocytosis is common and platelet counts may reach 500,000 to 1 million",
"      <span class=\"nowrap\">",
"       counts/microL.",
"      </span>",
"      Hemoconcentration and thrombocytosis may contribute to hypercoagulability and thrombotic complications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=see_link&amp;anchor=H5#H5\">",
"       \"Complications of idiopathic nephrotic syndrome in children\", section on 'Thromboembolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complement studies &mdash; Serum complement testing can be useful in the diagnosis of a specific renal or systemic disease that presents with nephrotic syndrome. Low C3 levels are typically seen in patients with membranoproliferative glomerulonephritis (MPGN) and postinfectious glomerulonephritis, while both low C3 and C4 are seen in patients with lupus nephritis. Serum complement is normal in patients with idiopathic nephrotic syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=see_link\">",
"       \"Poststreptococcal glomerulonephritis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolytes &mdash; Hyponatremia can be present, due to decreased free water excretion resulting from hypovolemic stimulation of the release of antidiuretic hormone (ADH).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Initial therapy versus renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of minimal change disease (MCD) can be made based upon clinical findings. In a multivariate analysis of 521 patients with nephrotic syndrome from the ISKDC, the following findings were predictive of MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age younger than six years of age",
"     </li>",
"     <li>",
"      Absence of hypertension",
"     </li>",
"     <li>",
"      Absence of hematuria by Addis count",
"     </li>",
"     <li>",
"      Normal complement levels",
"     </li>",
"     <li>",
"      Normal renal function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, over 90 percent of patients with MCD will respond to steroid therapy within eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these two observations, steroid therapy can be initiated in patients with a high probability of having steroid responsive idiopathic nephrotic syndrome without confirmation of the diagnosis by renal biopsy. Empiric steroid therapy can be given to patients who fulfill",
"    <strong>",
"     all",
"    </strong>",
"    of the following criteria; renal biopsy is performed before initiation of therapy in other patients.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age older than 1 year and less than 10 years of age",
"     </li>",
"     <li>",
"      None of the following clinical findings are present: hypertension, gross hematuria, and a marked elevation in serum creatinine",
"     </li>",
"     <li>",
"      Normal complement levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using this approach, invasive renal biopsy can be avoided in 80 percent of children between 1 and 10 years of age who present with nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37432/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with steroid-responsive nephrotic syndrome typically have a favorable outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because children with nephrotic syndrome initially present with edema, the other causes of childhood edema need to be considered in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef68106 \" href=\"mobipreview.htm?2/56/2957\">",
"     table 1",
"    </a>",
"    ). Nephrotic syndrome is distinguished from these causes of edema by the presence of nephrotic range proteinuria &gt;50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and hypoalbuminemia &lt;3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1657?source=see_link\">",
"     \"Pathophysiology and etiology of edema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Other causes of hypoalbuminemia, such as protein losing enteropathy or protein malnutrition (kwashiorkor). Hypoalbuminemia is also present in children with cirrhosis but the main cause of fluid retention is portal hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21527?source=see_link\">",
"       \"Pathogenesis of ascites in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased capillary permeability due to an allergic reaction or hereditary angioedema. The edema in this setting is typically focal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrotic syndrome is diagnosed by fulfilling two defining characteristics: urine protein excretion (nephrotic range proteinuria) &gt;50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, and hypoalbuminemia defined as serum albumin &lt;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/L).",
"      </span>",
"     </li>",
"     <li>",
"      Nephrotic syndrome is a result of injury to the glomerular filtration barrier, which increases its permeability. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common form of childhood nephrotic syndrome is idiopathic nephrotic syndrome. It is characterized by diffuse foot process effacement on electron microscopy and minimal changes (called minimal change disease [MCD]), primary focal segmental glomerulosclerosis (FSGS), or mesangial proliferation on light microscopy. MCD is particularly likely in children under the age of six. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Idiopathic nephrotic syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic nephrotic syndrome generally presents with edema, usually first noted as periorbital edema. The edema can become generalized and massive (anasarca) resulting in peripheral edema, ascites, umbilical or inguinal hernias, scrotal or vulva swelling,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pleural effusions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Macroscopic hematuria and elevated blood pressure may be present. The presence of either one of these findings makes it less likely that MCD is present, and another renal disease should be considered. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of childhood nephrotic syndrome is generally based upon the characteristic clinical and laboratory findings of edema, nephrotic range proteinuria, and hypoalbuminemia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with nephrotic syndrome who have a high probability of having idiopathic nephritic syndrome based upon clinical and laboratory findings, we recommend empiric therapy with oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      , thus avoiding renal biopsy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Renal biopsy is performed in patients who failed to respond to steroid therapy (steroid-resistant nephrotic syndrome) and in those who are less likely to initially respond to steroid therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Initial therapy versus renal biopsy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link&amp;anchor=H22#H22\">",
"       \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Steroid-resistant nephrotic syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The differential diagnosis includes other diseases that present with edema; these disorders are easily differentiated from nephrotic syndrome by the presence of nephrotic range proteinuria and hypoalbuminemia (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/1\">",
"      Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007; 119:e907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/2\">",
"      El Bakkali L, Rodrigues Pereira R, Kuik DJ, et al. Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature. Pediatr Nephrol 2011; 26:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/3\">",
"      Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/4\">",
"      Kashgarian M, Hayslett JP, Siegel NJ. Lipoid nephrosis and focal sclerosis distinct entities or spectrum of disease. Nephron 1974; 13:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/5\">",
"      The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/6\">",
"      White RH, Glasgow EF, Mills RJ. Clinicopathological study of nephrotic syndrome in childhood. Lancet 1970; 1:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/7\">",
"      Ingulli E, Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 1991; 5:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/8\">",
"      Filler G, Young E, Geier P, et al. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis 2003; 42:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/9\">",
"      Bonilla-Felix M, Parra C, Dajani T, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int 1999; 55:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/10\">",
"      McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol 2001; 16:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/11\">",
"      White RH. The familial nephrotic syndrome. I. A European survey. Clin Nephrol 1973; 1:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/12\">",
"      Moncrieff MW, White RH, Glasgow EF, et al. The familial nephrotic syndrome. II. A clinicopathological study. Clin Nephrol 1973; 1:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/13\">",
"      Vande Walle JG, Donckerwolcke RA, van Isselt JW, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/14\">",
"      Kim SW, Fr&oslash;kiaer J, Nielsen S. Pathogenesis of oedema in nephrotic syndrome: role of epithelial sodium channel. Nephrology (Carlton) 2007; 12 Suppl 3:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/15\">",
"      YAMAUCHI H, HOPPER J Jr. HYPOVOLEMIC SHOCK AND HYPOTENSION AS A COMPLICATION IN THE NEPHROTIC SYNDROME. REPORT OF TEN CASES. Ann Intern Med 1964; 60:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37432/abstract/16\">",
"      Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009; 124:747.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6101 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37432=[""].join("\n");
var outline_f36_35_37432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms of glomerular injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanisms of proteinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Idiopathic nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Secondary nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Urine tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Urine protein excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Serum proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Lipids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Estimation of GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Initial therapy versus renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6101|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/9/10399\" title=\"figure 1\">",
"      Protein filtration in FGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6101|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/9/13459\" title=\"picture 1\">",
"      Glomerular capillary wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/20/12617\" title=\"picture 2\">",
"      Light microscopy in minimal change disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/6/20584\" title=\"picture 3\">",
"      Electron microscopy in minimal change disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/56/2957\" title=\"table 1\">",
"      Causes edema childhood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/18/16673?source=related_link\" title=\"calculator 1\">",
"      Calculator: Urinary protein excretion estimation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=related_link\">",
"      Complications of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11238?source=related_link\">",
"      Evaluation of a child with glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=related_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41717?source=related_link\">",
"      Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1657?source=related_link\">",
"      Pathophysiology and etiology of edema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5556?source=related_link\">",
"      Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=related_link\">",
"      Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21354?source=related_link\">",
"      Steroid-resistant idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_35_37433="Overview of the hereditary ataxias";
var content_f36_35_37433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the hereditary ataxias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37433/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37433/contributors\">",
"     Puneet Opal, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37433/contributors\">",
"     Huda Y Zoghbi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37433/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37433/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37433/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37433/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/35/37433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hereditary ataxias are a genetically heterogeneous group of diseases that may be difficult to distinguish clinically because they are all characterized by motor incoordination resulting from dysfunction of the cerebellum and its connections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/1\">",
"     1",
"    </a>",
"    ]. With the identification of the gene defects in many of these disorders, the diagnosis now is made more often by genetic testing.",
"   </p>",
"   <p>",
"    The hereditary ataxias have traditionally been divided into two main classes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ataxia caused by underlying inborn errors of metabolism; these disorders usually are inherited in an autosomal recessive manner and typically present in childhood.",
"     </li>",
"     <li>",
"      Progressive degenerative ataxias not due to inborn errors of metabolism. This group of disorders, which are more common, are divided by their mode of inheritance into autosomal dominant, autosomal recessive, X-linked, and mitochondrial forms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hereditary ataxias caused by inborn errors of metabolism and the episodic, X-linked, and mitochondrial ataxias are discussed in this topic.",
"   </p>",
"   <p>",
"    The National Ataxia Foundation (",
"    <a class=\"external\" href=\"file://www.ataxia.org/\">",
"     www.ataxia.org",
"    </a>",
"    ), the Friedreich Ataxia Research Alliance (",
"    <a class=\"external\" href=\"file://www.curefa.org/\">",
"     www.curefa.org",
"    </a>",
"    ), and other nonprofit organizations such as the Worldwide Education and Awareness for Movement Disorders (",
"    <a class=\"external\" href=\"file://www.wemove.org/\">",
"     www.wemove.org",
"    </a>",
"    ) provide important information for patients and the larger public.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AUTOSOMAL DOMINANT ATAXIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common autosomal dominant ataxias are the spinocerebellar ataxias. Other causes include dentatorubral-pallidoluysian atrophy (DRPLA), which is common in Japan, and the ataxic variant of the Gerstmann-Str&auml;ussler-Scheinker syndrome, a prion disease. These disorders are briefly reviewed here, and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=see_link\">",
"     \"The spinocerebellar ataxias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than 20 types of spinocerebellar ataxia (and the number probably will continue to grow) with characteristic clinical and genetic abnormalities have been identified. Rather than representing an enzyme deficiency, some of these disorders are caused by trinucleotide (or, in SCA10, pentanucleotide) repeat expansion within the disease-causing gene (",
"    <a class=\"graphic graphic_table graphicRef74269 \" href=\"mobipreview.htm?10/59/11198\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common are CAG repeats in the coding region that encode for polyglutamine tracts in the protein products, similar to that seen in Huntington disease. Expansion of CAG repeats is thought to produce a toxic \"gain of function\" (ie, disease develops because the mutant form of the protein gains a new function, not because the protein loses its normal function). The repeats show both somatic and germline instability. As a result, successive generations of affected families experience anticipation, a phenomenon characterized by earlier onset and a progressively worse phenotype in subsequent generations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AUTOSOMAL RECESSIVE ATAXIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common autosomal recessive ataxias are Friedreich ataxia and ataxia-telangiectasia. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=see_link\">",
"     \"Friedreich ataxia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less frequent causes are xeroderma pigmentosum and Cockayne syndrome which, like ataxia-telangiectasia, are caused by defects in DNA repair mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link&amp;anchor=H24#H24\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'DNA repair disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of these disorders at some point have prominent non-neurologic manifestations, but Friedreich ataxia and ataxia-telangiectasia may be confused in the early stages of the disease. Diagnostic criteria have been proposed for ataxia-telangiectasia (",
"    <a class=\"graphic graphic_table graphicRef57053 \" href=\"mobipreview.htm?40/62/41963\">",
"     table 2",
"    </a>",
"    ), and the two disorders can be distinguished by genetic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As already noted, ataxias due to underlying inborn errors of metabolism usually are inherited in an autosomal recessive manner. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Ataxias caused by inborn errors of metabolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     X-LINKED ATAXIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked progressive ataxias are a heterogeneous group of rare disorders. Some are pure cerebellar syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], while others encompass additional neurologic abnormalities such as spasticity, deafness, mental retardation, or dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The genetic loci remain unknown in most of these disorders, with the exception of an early onset X-linked ataxia that is associated with deafness and loss of vision and links to locus Xq21.2-q24 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the X-linked diseases primarily are expressed in males, a small percentage of females have some symptoms because of skewed inactivation of the X chromosome bearing the normal allele. Other patients have ataxia combined with systemic abnormalities such as sideroblastic anemia and adrenal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     X-linked sideroblastic anemia with ataxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked sideroblastic anemia with ataxia is a recessive disorder characterized by relatively mild anemia, unresponsiveness to pyridoxine, and nonprogressive cerebellar ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=see_link\">",
"     \"Causes of congenital and acquired sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The molecular defect resides at Xq13 in the ABC7 transporter gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The role of the ABC7 protein, an ATP-binding cassette transporter, in human erythroid cells is not yet defined. The yeast ortholog of the ABC7 protein is involved in the generation of cytosolic iron-sulfur cluster-containing proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/12\">",
"     12",
"    </a>",
"    ]. How such a defect might lead to the phenotype of X-linked sideroblastic anemia with ataxia remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adrenoleukodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive ataxia and incoordination is an atypical presentation of adrenoleukodystrophy, an X-linked recessive disorder characterized by progressive neurologic dysfunction and primary adrenal insufficiency. This disorder is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=see_link&amp;anchor=H10#H10\">",
"     \"Adrenoleukodystrophy\", section on 'Other presentations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MITOCHONDRIAL ATAXIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain mitochondrial disorders can present with a progressive or intermittent ataxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Leigh syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leigh syndrome (subacute necrotizing encephalomyelopathy) is an inherited neurodegenerative disorder of infancy or childhood that is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link&amp;anchor=H21#H21\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Leigh syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, this disorder is characterized by developmental delay or psychomotor regression, signs of brainstem dysfunction, ataxia, dystonia, external ophthalmoplegia, seizures, lactic acidosis, vomiting, and weakness. Peripheral neuropathy with reduced nerve conduction velocity and demyelination also are frequent findings. The prognosis is poor, with survival often being a matter of months after disease onset. Histologic examination reveals bilateral, symmetric necrotizing lesions in the basal ganglia, thalamus, brainstem, and spinal cord. Magnetic resonance imaging shows abnormal white matter signal in the putamen, basal ganglia, and brainstem with T2 images.",
"   </p>",
"   <p>",
"    The Leigh syndrome phenotype appears to be related to altered mitochondrial metabolism. Alterations in the mitochondrial respiratory chain complex I, pyruvate dehydrogenase complex (PDHC), or in mitochondrial DNA (mtDNA) have been associated with autosomal, X-linked, or mtDNA mutations (maternally-inherited Leigh syndrome). A deficiency in cytochrome c oxidase (COX), the fourth multisubunit complex of the respiratory chain, is a common finding that is inherited as an autosomal recessive trait. Mutations in SURF1, a gene located on chromosome 9q34, have been identified in many COX deficient patients with Leigh syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link&amp;anchor=H21#H21\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Leigh syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ataxia and myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia and myoclonus can be produced by a variety of mitochondrial lesions. They include large deletions and duplications characteristic of Kearns-Sayre syndrome and maternally-inherited point mutations in mitochondrial genes encoding tRNA, the MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) and MERRF (myoclonic epilepsy with ragged red fibers) syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. In MELAS, for example, the genetic defect alters amino acid incorporation into the subunits of the oxidative phosphorylation system that are synthesized in the mitochondria, resulting in altered function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/13\">",
"     13",
"    </a>",
"    ]. In MERRF, on the other hand, an impairment in mitochondrial calcium homeostasis occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ATAXIAS CAUSED BY INBORN ERRORS OF METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous hereditary ataxias appear to be caused by inborn errors of metabolism. These ataxias tend to have recessive inheritance, as enzymatic activity of 50 percent in heterozygotes is sufficient for most metabolic pathways to proceed.",
"   </p>",
"   <p>",
"    The metabolic pathways involved in these disorders typically have numerous functions. As a result, ataxia is just one component of the clinical phenotype, which, taken as a whole, often points toward the underlying defect. The clinical phenotype can be divided into two general groups: the intermittent ataxias that occur with exacerbations of the underlying biochemical abnormal and the chronic progressive ataxias that are induced specific enzyme deficiencies (",
"    <a class=\"graphic graphic_table graphicRef56126 \" href=\"mobipreview.htm?21/25/21917\">",
"     table 3",
"    </a>",
"    ). A review of the individual disorders is beyond the scope of this discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Intermittent ataxias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of intermittent ataxias are the aminoacidurias resulting from mutations in urea cycle enzymes, which lead to hyperammonemia, and disorders of pyruvate and lactate metabolism (",
"    <a class=\"graphic graphic_table graphicRef56126 \" href=\"mobipreview.htm?21/25/21917\">",
"     table 3",
"    </a>",
"    ). Affected infants with all of these conditions typically display mental retardation and developmental delay. Nevertheless, establishing the correct diagnosis is important because supportive measures differ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Urea cycle enzyme deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with urea cycle enzyme deficiencies typically present with acute neurologic deterioration and hypotonia. Older children may have clumsiness, vomiting, and headaches. In addition, seizures, involuntary movements, and ptosis can occur at the peaks of hyperammonemia, usually induced by stress or ingestion of protein. Inheritance of urea cycle deficits is autosomal recessive, with the important exception of the relatively common ornithine transcarbamylase deficiency, which is X-linked. However, some female carriers with OTC convert less ammonia nitrogen to urea and are symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20248?source=see_link\">",
"     \"Urea cycle disorders: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Aminoacidurias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia may be seen in children with aminoaciduria, such as intermittent branched-chain ketoaciduria and isovaleric acidemia. This ataxic picture often is combined with seizures, episodic vomiting, and lethargy, similar to that seen in children with urea cycle deficits. The urine usually has a characteristic odor.",
"   </p>",
"   <p>",
"    Hartnup disease is a pathogenetically different cause of ataxia, resulting from a defect in renal and intestinal transport of neutral amino acids rather than a metabolic defect. This disorder also is associated with niacin deficiency, often leading to symptoms of pellagra (such as rash and confusion). Hartnup disease results from mutations in the SLC6A19 gene, which encodes for a sodium-dependent neutral amino acid transporter that is primarily expressed in the kidney and intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Disorders of pyruvate and lactate metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyruvate dehydrogenase (PDH) deficiency, a less common cause of metabolic intermittent ataxia, is characterized by lactic acidosis, seizures, mental retardation, ataxia, and spasticity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/24\">",
"     24",
"    </a>",
"    ]. This condition typically is caused by a mutation in PDHA1, the gene for the E1 alpha subunit of the PDH enzyme complex (Xp22.2-p22.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/25\">",
"     25",
"    </a>",
"    ]. Other less common genetic defects associated with PDH deficiency have been reported, including mutations in the E1 beta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/26\">",
"     26",
"    </a>",
"    ], E2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/27\">",
"     27",
"    </a>",
"    ], and E3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/28\">",
"     28",
"    </a>",
"    ] subunits, the E3 binding protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/29\">",
"     29",
"    </a>",
"    ], and in the PDH phosphatase enzyme that regulates the PDH complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/25/9618?source=see_link\">",
"     Biotin",
"    </a>",
"    -responsive multiple carboxylase deficiency is an autosomal recessive ataxia, characterized by ketoacidosis, dermatitis, seizures, myoclonus, and nystagmus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/31\">",
"     31",
"    </a>",
"    ]. The infantile form can be caused by a variety of mutations in the holocarboxylase synthetase gene at locus 21q22 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This enzyme catalyzes the fixation of biotin to inactive apocarboxylases, producing four active carboxylases (including pyruvate carboxylase). In children with late onset (usually juvenile) disease, the defect appears to lie in biotinidase, which catalyzes the removal of biotin from the carboxylases, thereby generating biotin for reutilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The biotinidase gene is located on chromosome 3p25 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic ataxias usually are diagnosed by screening biochemical tests when the neurologic abnormalities are first noticed. Based on a positive family history, OTC deficiency and several of the hyperammonemias can be diagnosed from blood samples taken in utero. Pyruvate dehydrogenase deficiency can, in addition, be corroborated by a relatively simple biochemical assay on cultured fibroblasts. Despite the identification of individual gene defects, genetic testing, at least at present, is impractical because of the numerous mutations in the relevant genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the underlying defect usually cannot be corrected, many of the intermittent ataxias can be indirectly treated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive therapy for the urea cycle disorders consists of hydration and dietary protein restriction. No treatment exists for the underlying enzyme deficiency in these disorders except for liver transplantation or, perhaps in the future, hepatocyte transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/12/31944?source=see_link\">",
"       \"Hepatocyte transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of the aminoacidurias consists of a high-protein diet. In addition, children with Hartnup disease are given niacin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/27/38322?source=see_link\">",
"       nicotinamide",
"      </a>",
"      ) supplementation.",
"     </li>",
"     <li>",
"      Among the disorders of pyruvate and lactate metabolism, pyruvate dehydrogenase deficiency can be treated with a ketogenic diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/39\">",
"       39",
"      </a>",
"      ] and dichloroacetate, which increases the activity of pyruvate dehydrogenase by stabilizing the mutant subunit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. Both infantile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/42,43\">",
"       42,43",
"      </a>",
"      ] and late onset multiple carboxylase deficiency can be treated with pharmacologic doses of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/25/9618?source=see_link\">",
"       biotin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/35,44,45\">",
"       35,44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Possible gene therapies are still experimental [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Progressive ataxias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive ataxias induced by catalytic deficiency can be seen in a variety of diseases (",
"    <a class=\"graphic graphic_table graphicRef56126 \" href=\"mobipreview.htm?21/25/21917\">",
"     table 3",
"    </a>",
"    ). These disorders typically present in later childhood or adolescence, unlike the intermittent ataxias. The probable explanation for this difference is that cumulative damage must reach a threshold before the clinical signs appear.",
"   </p>",
"   <p>",
"    Storage diseases predominate in this group and include Niemann-Pick disease type C, Wilson disease, metachromatic leukodystrophy, the heterogeneous ceroid lipofuscinosis and hexosaminidase deficiencies (eg, Tay-Sachs disease, Sandhoff disease), and",
"    <span class=\"nowrap\">",
"     adrenoleukodystrophy/adrenomyeloneuropathy",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef56126 \" href=\"mobipreview.htm?21/25/21917\">",
"     table 3",
"    </a>",
"    ). Some of these disorders are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link\">",
"     \"Hereditary neuropathies associated with generalized disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20489?source=see_link\">",
"     \"Overview of Niemann-Pick disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of a particular storage disease is usually made from the clinical picture in conjunction with histopathologic findings or biochemical tests. In",
"    <span class=\"nowrap\">",
"     adrenoleukodystrophy/adrenomyeloneuropathy,",
"    </span>",
"    for example, the disease is suspected from the X-linked inheritance and confirmed by elevated serum very long-chain fatty acid concentrations. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'X-linked ataxias'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In Niemann-Pick disease type C (NPC), the diagnosis may be suspected based upon the finding of vertical supranuclear gaze palsy, which is virtually always present in patients with NPC and ataxia. Additional features include splenomegaly and large, lipid-laden foam cells in bone marrow. In Wilson disease, important findings include hepatomegaly and Kayser-Fleischer rings on slit lamp examination (",
"    <a class=\"graphic graphic_picture graphicRef65925 \" href=\"mobipreview.htm?19/26/19887\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20489?source=see_link\">",
"     \"Overview of Niemann-Pick disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28806?source=see_link\">",
"     \"Supranuclear disorders of gaze in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatable diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;No cure has been found for the ataxias induced by storage defects, but specific measures can at least halt progression in a variety of disorders. The following are some examples.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wilson disease &mdash; Wilson disease is associated with tissue copper accumulation caused by mutations in the gene for ATP7B, a copper transporting ATPase. Treatment is given in two phases: removal the tissue copper that has accumulated and then prevention of reaccumulation. Copper removal is achieved by the administration of potent chelators. The primary chelator that has been used is D-penicillamine. However, approximately 30 percent of patients do not tolerate long-term therapy, and it may not be the treatment of choice in patients with neurologic symptoms. Another chelator,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/46/14052?source=see_link\">",
"       trientine",
"      </a>",
"      , has generally been used as a second-line agent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14088?source=see_link\">",
"       \"Tests used in the diagnosis of Wilson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ataxia with vitamin E deficiency &mdash; Vitamin E deficiency from a variety of causes (eg, malabsorption) can lead to ataxia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. Several hereditary ataxias also are associated with vitamin E deficiency. The neurologic injury in these disorders may be related to low vitamin E content [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/49\">",
"       49",
"      </a>",
"      ]. Ataxia with vitamin E deficiency (AVED) is an autosomal recessive disease caused by mutations in the alpha tocopherol transfer protein gene on chromosome 8q13.1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. It can present as a slowly progressive ataxia syndrome with neuropathy that can resemble Friedreich ataxia. In addition, some patients develop retinitis pigmentosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. High doses of vitamin E typically lead to neurologic improvement, although recovery may be slow and incomplete [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/54\">",
"       54",
"      </a>",
"      ]. Heterozygotes are phenotypically normal but have serum vitamin E concentrations 25 percent lower than normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Hypovitaminosis E results from fat malabsorption in patients with abetalipoproteinemia, an autosomal recessive disorder also known as Bassen-Kornzweig disease. The disease is caused by mutations in the microsomal triglyceride transfer protein gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/55\">",
"       55",
"      </a>",
"      ]. Defective assembly and secretion of apolipoprotein B (apo B) and apo-B-containing lipoproteins leads to impaired fat absorption, very low serum concentrations of cholesterol and very low-density lipoprotein (VLDL) triglyceride, and absent serum beta lipoprotein. The neurologic manifestations include progressive retinal degeneration (caused by coexisting vitamin A deficiency), peripheral neuropathy, and ataxia. Supplementation with vitamin E and the other fat-soluble vitamins early in the clinical course may improve the neuropathy and retinopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link&amp;anchor=H10#H10\">",
"       \"Hereditary neuropathies associated with generalized disorders\", section on 'Abetalipoproteinemia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A similar autosomal recessive ataxic syndrome with vitamin E deficiency occurs in patients with familial hypobetalipoproteinemia in which a mutation in the apo B gene is present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Interestingly, some mutations produce no symptoms and are associated with normal serum vitamin E concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cerebrotendinous xanthomatosis &mdash; Cerebrotendinous xanthomatosis is a relatively rare autosomal recessive cause of progressive ataxia. It is characterized by a block in bile acid synthesis caused by mutations in the mitochondrial sterol 27-hydroxylase gene on chromosome 2q33. The clinical manifestations include ataxia, neuropathy, cataracts, Achilles tendon xanthomas, and accelerated atherosclerosis. The diagnosis is suggested by elevated serum cholestanol in the presence of normal serum cholesterol and can be confirmed by genetic testing. Cholestanol is thought to be responsible for the neurologic toxicity. Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"       chenodeoxycholic acid",
"      </a>",
"      can markedly reduce both serum and cerebrospinal fluid cholestanol and appears to halt progression of the disease. It should be started early because improvement in established disease is uncommon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/4/34888?source=see_link\">",
"       \"Cerebrotendinous xanthomatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Refsum disease &mdash; Refsum disease is another treatable progressive ataxia. It should be suspected when a patient with autosomal recessive ataxia presents with the additional triad of ichthyosis, retinitis pigmentosa, and neuropathy. Patients with Refsum disease are unable to degrade phytanic acid caused by, in classical disease, deficient activity of phytanoyl-CoA hydroxylase (PhyH), a peroxisomal enzyme that catalyzes the first step of phytanic acid alpha-oxidation; this abnormality is caused by mutations in the PHYH gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. Strict reduction in dietary phytanic acid intake may be associated with a significant improvement in both the peripheral neuropathy and ataxia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link&amp;anchor=H13#H13\">",
"       \"Hereditary neuropathies associated with generalized disorders\", section on 'Refsum disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EPISODIC ATAXIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are seven varieties of dominantly inherited episodic ataxias (EAs), called EA1 through EA7. Of these, EA1 and EA2 account for the majority of reported cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/61\">",
"     61",
"    </a>",
"    ]. The diagnosis of episodic ataxia is typically made based upon the history and clinical features. Molecular genetic testing is clinically available for some of these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/62\">",
"     62",
"    </a>",
"    ]. Both EA1 and EA2 respond to treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    (250 to 750",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/63-67\">",
"     63-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284243695\">",
"    <span class=\"h2\">",
"     Episodic ataxia type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with EA1 present with brief episodes of unsteadiness lasting for only a few minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/9\">",
"     9",
"    </a>",
"    ]. These spells, often accompanied by myokymia (rippling of muscles), are frequently induced by exercise, stress, and caffeine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/68\">",
"     68",
"    </a>",
"    ]. Neurologic function is normal or near normal between attacks. Disease onset is usually late childhood or adolescence.",
"   </p>",
"   <p>",
"    The genetic basis for EA1 is the presence of point mutations in a voltage-gated potassium channel gene, KCNA1, located on chromosome 12p13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Molecular genetic testing for KCNA1 mutations is clinically available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/71\">",
"     71",
"    </a>",
"    ]. Typically, the only pathological correlate is minimal atrophy of the anterior cerebellar vermis. A mouse model of EA1 has been engineered that may lead to important insights into pathogenesis and therapeutic strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284243702\">",
"    <span class=\"h2\">",
"     Episodic ataxia type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with EA2 have prolonged attacks of ataxia that can last from a few hours to a few days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/73\">",
"     73",
"    </a>",
"    ]. Severe vertigo, nausea, and vomiting often are part of the attacks, and gaze-evoked, rebound, or downbeat nystagmus may be evident not only during but also between attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/65\">",
"     65",
"    </a>",
"    ]. These episodes appear to produce cumulative cerebellar injury, as patients often develop persistent cerebellar symptoms and cerebellar atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/74\">",
"     74",
"    </a>",
"    ]. Thus, subtle cerebellar signs, such as nystagmus and mild clumsiness, and the longer duration of episodes suggest EA2 rather than EA1. The manifestations and rate of progression are variable but usually relatively uniform within a kindred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/65\">",
"     65",
"    </a>",
"    ]. As with EA1, disease onset is usually late childhood or adolescence.",
"   </p>",
"   <p>",
"    EA2 is caused by mutations in the CACNA1A gene that encodes the alpha-1A subunit of a brain-specific",
"    <span class=\"nowrap\">",
"     P/Q-type",
"    </span>",
"    calcium channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/75-78\">",
"     75-78",
"    </a>",
"    ] or, in one family, in the gene for the beta-4 subunit of this channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/79\">",
"     79",
"    </a>",
"    ]. The alpha-1A subunit mutation also can occur de novo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/66\">",
"     66",
"    </a>",
"    ]. Mutations in the",
"    <span class=\"nowrap\">",
"     P/Q",
"    </span>",
"    calcium channel may cause episodic ataxia in EA2 by reducing calcium dependent neurotransmitter release in cerebellar Purkinje cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/80\">",
"     80",
"    </a>",
"    ]. Molecular genetic testing for CACNA1A mutations is clinically available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    is often effective for reducing the frequency of attacks. In addition, the potassium channel blocker",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6725?source=see_link\">",
"     dalfampridine",
"    </a>",
"    (4-aminopyridine) is beneficial, as shown in a randomized controlled trial of 10 patients with EA, including 7 patients with CACNA1A mutations; dalfampridine (5 mg three times a day) was significantly more effective for reducing attack frequency than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/82\">",
"     82",
"    </a>",
"    ]. In an earlier pilot study, dalfampridine completely prevented attacks of ataxia in two patients and markedly reduced attacks in one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/83\">",
"     83",
"    </a>",
"    ]. Two of these patients had previously developed an increased frequency of attacks despite treatment with acetazolamide. The proposed mechanism of dalfampridine is increased excitability of cerebellar Purkinje cells with subsequent increased release of the inhibitory neurotransmitter gamma aminobutyric acid (GABA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/83\">",
"     83",
"    </a>",
"    ]. No trials have compared dalfampridine with acetazolamide in EA2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284243709\">",
"    <span class=\"h2\">",
"     Episodic ataxia types 3 to 7",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodic ataxia type 3 &mdash; Patients with EA3 (originally designated as EA4) have recurrent brief (minutes) attacks of vestibular ataxia, vertigo, tinnitus, and interictal myokymia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/67\">",
"       67",
"      </a>",
"      ]. The age of onset is variable. The attacks appear to be responsive to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/57/28566?source=see_link\">",
"       acetazolamide",
"      </a>",
"      . Genome-wide screening suggests linkage to chromosome 1q42 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Episodic ataxia type 4 &mdash; Patients with EA4 (previously designated as EA3 and also known as periodic vestibulocerebellar ataxia) have recurrent attacks of vertigo, diplopia, tinnitus and ataxia beginning in early adulthood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/67,85\">",
"       67,85",
"      </a>",
"      ]. Ocular manifestations include defective smooth pursuit and gaze-evoked nystagmus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/86\">",
"       86",
"      </a>",
"      ]. Unlike the other EAs, this form appears to be unresponsive to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/57/28566?source=see_link\">",
"       acetazolamide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Episodic ataxia type 5 &mdash; EA5 has clinical features similar to those of EA2, with attacks lasting hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/87\">",
"       87",
"      </a>",
"      ]. EA5 is caused by a mutation in the CACNB4 gene on chromosome 2q22-23; the same mutation was identified in another family with generalized epilepsy but no ataxia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Episodic ataxia type 6 &mdash; EA6 is caused by a heterozygous mutation in the SLC1A3 gene, a member of the solute carrier family that encodes excitatory amino acid transporter 1 (EAAT1), and was identified in an adolescent patient with episodic ataxia, seizures, migraine and alternating hemiplegia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/88\">",
"       88",
"      </a>",
"      ]. Another SLC1A3 mutation was found in three family members who had episodic ataxia but no seizures, migraine, or alternating hemiplegia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Episodic ataxia type 7 &mdash; EA7 was identified in a single family and has clinical features similar to those of EA2, with the exception that neurologic examination is normal between attacks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/90\">",
"       90",
"      </a>",
"      ]. Linkage analysis suggested chromosome 19q13 as the gene locus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Overlap with other paroxysmal neurologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in genes encoding ion channels, ion pumps, and glutamate transporters have been associated with EAs, familial hemiplegic migraine (FHM), seizures, and spinocerebellar ataxia (SCA). The following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Different mutations in the CACNA1A gene encoding the alpha-1A subunit of the",
"      <span class=\"nowrap\">",
"       P/Q",
"      </span>",
"      type calcium channel have been identified in EA2, FHM type 1, and SCA type 6.",
"     </li>",
"     <li>",
"      Some patients with EA2 have episodic hemiplegia that may be associated with migraine headaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Co-occurrence of FHM with childhood epilepsy and cerebellar ataxia in a single family with a CACNA1A mutation has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As mentioned above in the discussion of EA6, a heterozygous mutation in the SLC1A3 gene was identified in a single adolescent patient with episodic ataxia, seizures, migraine and alternating hemiplegia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      EA, FHM, and SCA are often associated with cerebellar atrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disturbances of neuronal excitability may be the underlying mechanism causing these different clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/60/17354?source=see_link&amp;anchor=H81876416#H81876416\">",
"     \"Hemiplegic migraine\", section on 'Familial hemiplegic migraine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=see_link\">",
"     \"The spinocerebellar ataxias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER DISORDERS WITH ATAXIA AND MYOCLONUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Unverricht-Lundborg disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unverricht-Lundborg disease (ULD) is one form of progressive myoclonus epilepsy (PME) that is characterized by myoclonic seizures and progressive ataxia. ULD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/40/18058?source=see_link&amp;anchor=H36#H36\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Unverricht-Lundborg disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sialidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sialidosis (neuraminidase deficiency, mucolipidosis type I) is an autosomal recessive disorder characterized by a defect in the sialidase (neuraminidase) gene on chromosome 6p21.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37433/abstract/93\">",
"     93",
"    </a>",
"    ]. Two main clinical variants of sialidosis have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sialidosis type I is characterized by late onset with myoclonus and bilateral macular cherry-red spots.",
"     </li>",
"     <li>",
"      Sialidosis type II is characterized by infantile onset with skeletal dysplasia, mental retardation and hepatosplenomegaly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140854770\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hereditary ataxias are a genetically heterogeneous group of diseases that are characterized by motor incoordination resulting from dysfunction of the cerebellum and its connections. The hereditary ataxias have traditionally been divided into those caused by underlying inborn errors of metabolism (generally autosomal recessive) and progressive ataxias not due to inborn errors of metabolism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common autosomal dominant ataxias are the spinocerebellar ataxias (",
"      <a class=\"graphic graphic_table graphicRef74269 \" href=\"mobipreview.htm?10/59/11198\">",
"       table 1",
"      </a>",
"      ). Other causes include dentatorubral-pallidoluysian atrophy and the ataxic variant of the Gerstmann-Str&auml;ussler-Scheinker syndrome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Autosomal dominant ataxias'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=see_link\">",
"       \"The spinocerebellar ataxias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common autosomal recessive ataxias are Friedreich ataxia and ataxia-telangiectasia. Less frequent causes are xeroderma pigmentosum and Cockayne syndrome which, like ataxia-telangiectasia, are caused by defects in DNA repair mechanisms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Autosomal recessive ataxias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      X-linked progressive ataxias are a heterogeneous group of rare disorders. Some are pure cerebellar syndromes, while others encompass additional neurologic abnormalities such as spasticity, deafness, mental retardation, or dementia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'X-linked ataxias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain mitochondrial disorders can present with a progressive or intermittent ataxia (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mitochondrial ataxias'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Numerous hereditary ataxias appear to be caused by inborn errors of metabolism. These ataxias tend to have recessive inheritance, as enzymatic activity of 50 percent in heterozygotes is sufficient for most metabolic pathways to proceed (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Ataxias caused by inborn errors of metabolism'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most common causes of intermittent ataxias are the aminoacidurias resulting from mutations in urea cycle enzymes, which lead to hyperammonemia, and disorders of pyruvate and lactate metabolism (",
"      <a class=\"graphic graphic_table graphicRef56126 \" href=\"mobipreview.htm?21/25/21917\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Intermittent ataxias'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Progressive ataxias induced by catalytic deficiency can be seen in a variety of diseases. Storage diseases predominate in this group and include Niemann-Pick disease type C, Wilson disease, metachromatic leukodystrophy, the heterogeneous ceroid lipofuscinosis and hexosaminidase deficiencies, and",
"      <span class=\"nowrap\">",
"       adrenoleukodystrophy/adrenomyeloneuropathy",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef56126 \" href=\"mobipreview.htm?21/25/21917\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Progressive ataxias'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are seven varieties of dominantly inherited episodic ataxias (EAs), called EA1 through EA7. Of these, EA1 and EA2 account for the majority of reported cases. The diagnosis of episodic ataxia is typically made based upon the history and clinical features. Molecular genetic testing is clinically available for some of these disorders. Both EA1 and EA2 respond to treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/57/28566?source=see_link\">",
"       acetazolamide",
"      </a>",
"      (250 to 750",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Episodic ataxias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/1\">",
"      Brusse E, Maat-Kievit JA, van Swieten JC. Diagnosis and management of early- and late-onset cerebellar ataxia. Clin Genet 2007; 71:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/2\">",
"      Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol 2007; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/3\">",
"      Lutz R, Bodensteiner J, Schaefer B, Gay C. X-linked olivopontocerebellar atrophy. Clin Genet 1989; 35:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/4\">",
"      Spira PJ, McLeod JG, Evans WA. A spinocerebellar degeneration with X-linked inheritance. Brain 1979; 102:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/5\">",
"      Apak S, Y&uuml;ksel M, Ozmen M, et al. Heterogeneity of X-linked recessive (spino)cerebellar ataxia with or without spastic diplegia. Am J Med Genet 1989; 34:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/6\">",
"      Arts WF, Loonen MC, Sengers RC, Slooff JL. X-linked ataxia, weakness, deafness, and loss of vision in early childhood with a fatal course. Ann Neurol 1993; 33:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/7\">",
"      Kremer H, Hamel BC, van den Helm B, et al. Localization of the gene (or genes) for a syndrome with X-linked mental retardation, ataxia, weakness, hearing impairment, loss of vision and a fatal course in early childhood. Hum Genet 1996; 98:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/8\">",
"      Farlow MR, DeMyer W, Dlouhy SR, Hodes ME. X-linked recessive inheritance of ataxia and adult-onset dementia: clinical features and preliminary linkage analysis. Neurology 1987; 37:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/9\">",
"      Eunson LH, Rea R, Zuberi SM, et al. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol 2000; 48:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/10\">",
"      Pagon RA, Bird TD, Detter JC, Pierce I. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet 1985; 22:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/11\">",
"      Allikmets R, Raskind WH, Hutchinson A, et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999; 8:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/12\">",
"      Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood 2000; 96:3256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/13\">",
"      Flierl A, Reichmann H, Seibel P. Pathophysiology of the MELAS 3243 transition mutation. J Biol Chem 1997; 272:27189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/14\">",
"      Chomyn A, Enriquez JA, Micol V, et al. The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNALeu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes. J Biol Chem 2000; 275:19198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/15\">",
"      B&ouml;rner GV, Zeviani M, Tiranti V, et al. Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum Mol Genet 2000; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/16\">",
"      Chomyn A. The myoclonic epilepsy and ragged-red fiber mutation provides new insights into human mitochondrial function and genetics. Am J Hum Genet 1998; 62:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/17\">",
"      Brini M, Pinton P, King MP, et al. A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nat Med 1999; 5:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/18\">",
"      Mancuso M, Filosto M, Mootha VK, et al. A novel mitochondrial tRNAPhe mutation causes MERRF syndrome. Neurology 2004; 62:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/19\">",
"      Batshaw ML, Msall M, Beaudet AL, Trojak J. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr 1986; 108:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/20\">",
"      Yudkoff M, Daikhin Y, Nissim I, et al. In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J Clin Invest 1996; 98:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/21\">",
"      Gaspari R, Arcangeli A, Mensi S, et al. Late-onset presentation of ornithine transcarbamylase deficiency in a young woman with hyperammonemic coma. Ann Emerg Med 2003; 41:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/22\">",
"      Kleta R, Romeo E, Ristic Z, et al. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet 2004; 36:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/23\">",
"      Seow HF, Br&ouml;er S, Br&ouml;er A, et al. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet 2004; 36:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/24\">",
"      Robinson BH, MacMillan H, Petrova-Benedict R, Sherwood WG. Variable clinical presentation in patients with defective E1 component of pyruvate dehydrogenase complex. J Pediatr 1987; 111:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/25\">",
"      Dahl HH, Brown GK, Brown RM, et al. Mutations and polymorphisms in the pyruvate dehydrogenase E1 alpha gene. Hum Mutat 1992; 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/26\">",
"      Brown RM, Head RA, Boubriak II, et al. Mutations in the gene for the E1beta subunit: a novel cause of pyruvate dehydrogenase deficiency. Hum Genet 2004; 115:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/27\">",
"      Head RA, Brown RM, Zolkipli Z, et al. Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: dihydrolipoamide acetyltransferase (E2) deficiency. Ann Neurol 2005; 58:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/28\">",
"      Hong YS, Korman SH, Lee J, et al. Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: possible beneficial effect of vitamin therapy. J Inherit Metab Dis 2003; 26:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/29\">",
"      Brown RM, Head RA, Brown GK. Pyruvate dehydrogenase E3 binding protein deficiency. Hum Genet 2002; 110:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/30\">",
"      Maj MC, MacKay N, Levandovskiy V, et al. Pyruvate dehydrogenase phosphatase deficiency: identification of the first mutation in two brothers and restoration of activity by protein complementation. J Clin Endocrinol Metab 2005; 90:4101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/31\">",
"      Aoki Y, Li X, Sakamoto O, et al. Identification and characterization of mutations in patients with holocarboxylase synthetase deficiency. Hum Genet 1999; 104:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/32\">",
"      Suzuki Y, Aoki Y, Ishida Y, et al. Isolation and characterization of mutations in the human holocarboxylase synthetase cDNA. Nat Genet 1994; 8:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/33\">",
"      Dupuis L, Leon-Del-Rio A, Leclerc D, et al. Clustering of mutations in the biotin-binding region of holocarboxylase synthetase in biotin-responsive multiple carboxylase deficiency. Hum Mol Genet 1996; 5:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/34\">",
"      Wolf B, Grier RE, Allen RJ, et al. Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency. Clin Chim Acta 1983; 131:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/35\">",
"      Wolf B, Heard GS, Weissbecker KA, et al. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol 1985; 18:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/36\">",
"      Pomponio RJ, Reynolds TR, Cole H, et al. Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency. Nat Genet 1995; 11:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/37\">",
"      Todo S, Starzl TE, Tzakis A, et al. Orthotopic liver transplantation for urea cycle enzyme deficiency. Hepatology 1992; 15:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/38\">",
"      Busuttil AA, Goss JA, Seu P, et al. The role of orthotopic liver transplantation in the treatment of ornithine transcarbamylase deficiency. Liver Transpl Surg 1998; 4:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/39\">",
"      Wexler ID, Hemalatha SG, McConnell J, et al. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology 1997; 49:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/40\">",
"      McCormick K, Viscardi RM, Robinson B, Heininger J. Partial pyruvate decarboxylase deficiency with profound lactic acidosis and hyperammonemia: responses to dichloroacetate and benzoate. Am J Med Genet 1985; 22:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/41\">",
"      Morten KJ, Beattie P, Brown GK, Matthews PM. Dichloroacetate stabilizes the mutant E1alpha subunit in pyruvate dehydrogenase deficiency. Neurology 1999; 53:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/42\">",
"      Suormala T, Fowler B, Duran M, et al. Five patients with a biotin-responsive defect in holocarboxylase formation: evaluation of responsiveness to biotin therapy in vivo and comparative biochemical studies in vitro. Pediatr Res 1997; 41:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/43\">",
"      Sakamoto O, Suzuki Y, Li X, et al. Relationship between kinetic properties of mutant enzyme and biochemical and clinical responsiveness to biotin in holocarboxylase synthetase deficiency. Pediatr Res 1999; 46:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/44\">",
"      Wastell HJ, Bartlett K, Dale G, Shein A. Biotinidase deficiency: a survey of 10 cases. Arch Dis Child 1988; 63:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/45\">",
"      Lott IT, Lottenberg S, Nyhan WL, Buchsbaum MJ. Cerebral metabolic change after treatment in biotinidase deficiency. J Inherit Metab Dis 1993; 16:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/46\">",
"      Ginn SL, Cunningham SC, Zheng M, et al. In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver. Gene Ther 2009; 16:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/47\">",
"      Sokol RJ, Guggenheim MA, Iannaccone ST, et al. Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis. N Engl J Med 1985; 313:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/48\">",
"      Satya-Murti S, Howard L, Krohel G, Wolf B. The spectrum of neurologic disorder from vitamin E deficiency. Neurology 1986; 36:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/49\">",
"      Traber MG, Sokol RJ, Ringel SP, et al. Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy. N Engl J Med 1987; 317:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/50\">",
"      Ouahchi K, Arita M, Kayden H, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet 1995; 9:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/51\">",
"      Gotoda T, Arita M, Arai H, et al. Adult-onset spinocerebellar dysfunction caused by a mutation in the gene for the alpha-tocopherol-transfer protein. N Engl J Med 1995; 333:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/52\">",
"      Yokota T, Shiojiri T, Gotoda T, et al. Friedreich-like ataxia with retinitis pigmentosa caused by the His101Gln mutation of the alpha-tocopherol transfer protein gene. Ann Neurol 1997; 41:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/53\">",
"      Mariotti C, Gellera C, Rimoldi M, et al. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol Sci 2004; 25:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/54\">",
"      Schuelke M, Mayatepek E, Inter M, et al. Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. J Pediatr 1999; 134:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/55\">",
"      Sharp D, Blinderman L, Combs KA, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993; 365:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/56\">",
"      Young SG, Hubl ST, Smith RS, et al. Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins. J Clin Invest 1990; 85:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/57\">",
"      Young SG, Bihain B, Flynn LM, et al. Asymptomatic homozygous hypobetalipoproteinemia associated with apolipoprotein B45.2. Hum Mol Genet 1994; 3:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/58\">",
"      Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet 1997; 17:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/59\">",
"      Mihalik SJ, Morrell JC, Kim D, et al. Identification of PAHX, a Refsum disease gene. Nat Genet 1997; 17:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/60\">",
"      Hungerb&uuml;hler JP, Meier C, Rousselle L, et al. Refsum's disease: management by diet and plasmapheresis. Eur Neurol 1985; 24:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/61\">",
"      Jen JC, Graves TD, Hess EJ, et al. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 2007; 130:2484.",
"     </a>",
"    </li>",
"    <li>",
"     Bird TD. Hereditary ataxia overview. In: GeneReviews [Internet]. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ataxias (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/63\">",
"      Jen J. Familial Episodic Ataxias and Related Ion Channel Disorders. Curr Treat Options Neurol 2000; 2:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/64\">",
"      Zasorin NL, Baloh RW, Myers LB. Acetazolamide-responsive episodic ataxia syndrome. Neurology 1983; 33:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/65\">",
"      Baloh RW, Yue Q, Furman JM, Nelson SF. Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p. Ann Neurol 1997; 41:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/66\">",
"      Yue Q, Jen JC, Thwe MM, et al. De novo mutation in CACNA1A caused acetazolamide-responsive episodic ataxia. Am J Med Genet 1998; 77:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/67\">",
"      Steckley JL, Ebers GC, Cader MZ, McLachlan RS. An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. Neurology 2001; 57:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/68\">",
"      Gancher ST, Nutt JG. Autosomal dominant episodic ataxia: a heterogeneous syndrome. Mov Disord 1986; 1:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/69\">",
"      Browne DL, Gancher ST, Nutt JG, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet 1994; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/70\">",
"      Scheffer H, Brunt ER, Mol GJ, et al. Three novel KCNA1 mutations in episodic ataxia type I families. Hum Genet 1998; 102:464.",
"     </a>",
"    </li>",
"    <li>",
"     Pessia M, Hanna MG. Episodic ataxia type 1. In: GeneReviews [Internet]. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ea1 (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/72\">",
"      Herson PS, Virk M, Rustay NR, et al. A mouse model of episodic ataxia type-1. Nat Neurosci 2003; 6:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/73\">",
"      Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/74\">",
"      Denier C, Ducros A, Vahedi K, et al. High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2. Neurology 1999; 52:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/75\">",
"      Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/76\">",
"      Spacey SD, Hildebrand ME, Materek LA, et al. Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann Neurol 2004; 56:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/77\">",
"      Wan J, Carr JR, Baloh RW, Jen JC. Nonconsensus intronic mutations cause episodic ataxia. Ann Neurol 2005; 57:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/78\">",
"      Riant F, Mourtada R, Saugier-Veber P, Tournier-Lasserve E. Large CACNA1A deletion in a family with episodic ataxia type 2. Arch Neurol 2008; 65:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/79\">",
"      Escayg A, De Waard M, Lee DD, et al. Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 2000; 66:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/80\">",
"      Kullmann DM. The neuronal channelopathies. Brain 2002; 125:1177.",
"     </a>",
"    </li>",
"    <li>",
"     Spacey S. Episodic ataxia type 2. In: GeneReviews [Internet]. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ea2 (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/82\">",
"      Strupp M, Kalla R, Claassen J, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 2011; 77:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/83\">",
"      Strupp M, Kalla R, Dichgans M, et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004; 62:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/84\">",
"      Cader MZ, Steckley JL, Dyment DA, et al. A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia. Neurology 2005; 65:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/85\">",
"      FARMER TW, MUSTIAN VM. Vestibulocerebellar ataxia. A newly defined hereditary syndrome with periodic manifestations. Arch Neurol 1963; 8:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/86\">",
"      Damji KF, Allingham RR, Pollock SC, et al. Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Arch Neurol 1996; 53:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/87\">",
"      Herrmann A, Braathen GJ, Russell MB. [Episodic ataxias]. Tidsskr Nor Laegeforen 2005; 125:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/88\">",
"      Jen JC, Wan J, Palos TP, et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 2005; 65:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/89\">",
"      de Vries B, Mamsa H, Stam AH, et al. Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake. Arch Neurol 2009; 66:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/90\">",
"      Kerber KA, Jen JC, Lee H, et al. A new episodic ataxia syndrome with linkage to chromosome 19q13. Arch Neurol 2007; 64:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/91\">",
"      Jen J, Yue Q, Nelson SF, et al. A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia. Neurology 1999; 53:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/92\">",
"      Kors EE, Melberg A, Vanmolkot KR, et al. Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation. Neurology 2004; 63:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37433/abstract/93\">",
"      Pshezhetsky AV, Richard C, Michaud L, et al. Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet 1997; 15:316.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6234 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37433=[""].join("\n");
var outline_f36_35_37433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H140854770\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AUTOSOMAL DOMINANT ATAXIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AUTOSOMAL RECESSIVE ATAXIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      X-LINKED ATAXIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      X-linked sideroblastic anemia with ataxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MITOCHONDRIAL ATAXIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Leigh syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ataxia and myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ATAXIAS CAUSED BY INBORN ERRORS OF METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intermittent ataxias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Urea cycle enzyme deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Aminoacidurias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Disorders of pyruvate and lactate metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Progressive ataxias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatable diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EPISODIC ATAXIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H284243695\">",
"      Episodic ataxia type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H284243702\">",
"      Episodic ataxia type 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H284243709\">",
"      Episodic ataxia types 3 to 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Overlap with other paroxysmal neurologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER DISORDERS WITH ATAXIA AND MYOCLONUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Unverricht-Lundborg disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sialidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H140854770\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6234\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6234|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/26/19887\" title=\"picture 1\">",
"      Kayser Fleischer ring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6234|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/59/11198\" title=\"table 1\">",
"      Characteristics of SCA types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/62/41963\" title=\"table 2\">",
"      Diagnosis ataxia telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/25/21917\" title=\"table 3\">",
"      Ataxias due to enzyme defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=related_link\">",
"      Causes of congenital and acquired sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/4/34888?source=related_link\">",
"      Cerebrotendinous xanthomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=related_link\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/60/17354?source=related_link\">",
"      Hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/12/31944?source=related_link\">",
"      Hepatocyte transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20489?source=related_link\">",
"      Overview of Niemann-Pick disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_35_37434="Overview of the management of chronic kidney disease in adults";
var content_f36_35_37434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of chronic kidney disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37434/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37434/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37434/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37434/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37434/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/35/37434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/35/37434/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/35/37434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with renal disease (whether acute or chronic) should undergo an assessment of renal function by estimating the glomerular filtration rate (GFR). This measurement is used clinically to evaluate the degree of renal impairment, to follow the course of the disease, and to assess the response to therapy. An attempt must also be made to obtain a specific diagnosis. The first step in this process is a careful urinalysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the general issues involved in the management of the patient with chronic kidney disease, including modalities to slow the rate of progression, will be presented here. The specific therapy of patients with particular renal diseases is discussed separately in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial injury to the kidney may result in a variety of clinical manifestations, ranging from asymptomatic hematuria to renal failure requiring dialysis. Many individuals fully recover and subsequently suffer from little or no sequelae. Poststreptococcal glomerulonephritis in children, for example, most frequently has a long-term benign prognosis. By comparison, some patients, such as those with lupus nephritis, experience repeated and chronic insults to the renal parenchyma, thereby resulting in lasting damage. Furthermore, others in whom the initial disease is either inactive or cured may still develop progressive renal disease due to hemodynamic and other mechanisms.",
"   </p>",
"   <p>",
"    In addition to variations in the activity of the individual diseases, these different manifestations are partly due to how the kidney responds to injury. The kidney is able to adapt to damage by increasing the filtration rate in the remaining normal nephrons, a process called adaptive hyperfiltration. As a result, the patient with mild renal insufficiency often has a normal or near-normal serum creatinine concentration. Additional homeostatic mechanisms (most frequently occurring within the renal tubules) permit the serum concentrations of sodium, potassium, calcium, and phosphorous and the total body water to also remain within the normal range, particularly among those with mild to moderate renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adaptive hyperfiltration, although initially beneficial, appears to result in long-term damage to the glomeruli of the remaining nephrons, which is manifest by proteinuria and progressive renal insufficiency. This process appears to be responsible for the development of renal failure among those in whom the original illness is either inactive or cured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/1\">",
"     1",
"    </a>",
"    ]. The institution of measures to help prevent this process, such as antihypertensive therapy with an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, may slow progressive disease and even preserve renal function. If these modalities are effective, the benefit is likely to be greatest if begun before a great deal of irreversible scarring has occurred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gradual decline in function in patients with chronic kidney disease (CKD) is initially asymptomatic. However, as previously mentioned, different signs and symptoms may be observed with advanced renal dysfunction, including volume overload, hyperkalemia, metabolic acidosis, hypertension, anemia, and bone disease. The onset of end-stage renal disease results in a constellation of signs and symptoms referred to as uremia.",
"   </p>",
"   <p>",
"    Manifestations of the uremic state include anorexia, nausea, vomiting, pericarditis, peripheral neuropathy, and central nervous system abnormalities (ranging from loss of concentration and lethargy to seizures, coma, and death). No direct correlation exists between the absolute serum levels of blood urea nitrogen (BUN) or creatinine, and the development of these symptoms. Some patients have relatively low levels (eg, a BUN of 60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [21.4",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    in an older patient) but are markedly symptomatic, while others have marked elevations (eg, a BUN of 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [50",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    but remain asymptomatic. To continue life, uremic patients require the institution of renal replacement therapy with hemodialysis, peritoneal dialysis, or renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all individuals have progressive loss of kidney function. Some studies show a high rate of progression, while others report relatively stable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The rate of progression of chronic kidney disease from one major stage to another varies based upon the underlying disease, presence or absence of comorbid conditions, treatments, socioeconomic status, individual genetics, ethnicity, and other factors.",
"   </p>",
"   <p>",
"    Using epidemiologic data, general estimates for the rate of transition from a GFR between 15 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 to end stage disease may be approximately 1.5 percent per year, while the rate of transition from a GFR above 60 to below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 may be approximately 0.5 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of both a low GFR plus dipstick positive proteinuria, versus either parameter alone, is associated with a significantly increased risk of progressive renal disease. This was shown in a retrospective study of the association between these measures and the 25-year incidence of end-stage renal disease of middle aged men originally studied in the Multiple Risk Factor Intervention Study (MRFIT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/7\">",
"     7",
"    </a>",
"    ]. The presence of 1+ dipstick proteinuria, 2+ dipstick proteinuria, estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2, and a low GFR plus 2+ proteinuria was associated with hazard ratios of 3.1, 15.7, 2.4, and 41, respectively, for the development of ESRD over a 25-year period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease (CKD) is defined as the presence of kidney damage (usually detected as urinary albumin excretion of 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or more, or equivalent)",
"    <strong>",
"     or",
"    </strong>",
"    decreased kidney function (defined as a glomerular filtration rate [GFR] less than 60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2)",
"    <strong>",
"     for three or more months",
"    </strong>",
"    , irrespective of the cause (",
"    <a class=\"graphic graphic_table graphicRef80632 \" href=\"mobipreview.htm?21/62/22509\">",
"     table 1",
"    </a>",
"    ). The persistence of the damage or decreased function for at least three months is necessary to distinguish CKD from acute kidney disease.",
"   </p>",
"   <p>",
"    Classification, or staging, of CKD provides a guide to management, including stratification of risk for progression and complications of CKD. Risk stratification is used to inform appropriate treatments and the intensity of monitoring and patient education. We agree with the 2012 KDIGO guidelines that state that among patients who are diagnosed using the criteria described above, staging of CKD should be done according to the following (",
"    <a class=\"graphic graphic_table graphicRef70597 \" href=\"mobipreview.htm?13/47/14076\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cause of disease",
"     </li>",
"     <li>",
"      Six categories of GFR (G stages)",
"     </li>",
"     <li>",
"      Three categories of albuminuria (A stages)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Staging patients with CKD according to cause, GFR, and albuminuria enhances risk stratification for the major complications of CKD (",
"    <a class=\"graphic graphic_figure graphicRef68921 \" href=\"mobipreview.htm?40/46/41701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58089 \" href=\"mobipreview.htm?27/44/28360\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A more detailed discussion of the definition and classification of CKD is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5594?source=see_link\">",
"     \"Definition and staging of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH CARDIOVASCULAR DISEASE, END-STAGE RENAL DISEASE, AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a large body of evidence that patients with CKD have a substantial increase in cardiovascular risk that can be in part explained by an increase in traditional risk factors such as hypertension, diabetes, and the metabolic syndrome. CKD alone is also an independent risk factor for cardiovascular disease. Among patients with CKD, the risk of death, particularly due to cardiovascular disease, is much higher than the risk of eventually requiring dialysis. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Close attention to the prevention and management of cardiovascular disease should occur among patients identified with chronic renal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/9\">",
"     9",
"    </a>",
"    ]. As an example, the increased intake of calcium (which is commonly given to treat hyperphosphatemia and may result in a high calcium-phosphorus product) may enhance coronary arterial calcification. Although controversial, this is thought by some to be associated with the development of coronary atherosclerosis, and is related to the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consequences of elevated serum phosphorus, calcium, and parathyroid hormone levels. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hyperphosphatemia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These and other observations have suggested that chronic kidney disease should be considered a coronary equivalent and that aggressive risk factor reduction should be part of standard therapy of patients with chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H6#H6\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'CKD as a CHD risk equivalent'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H11#H11\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Reduction of CHD risk in patients with CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CKD are also at increased risk for the development of end-stage renal disease (ESRD) as well as all-cause mortality. In some subsets of individuals with CKD, the risk of ESRD exceeds the risk of mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H599734827#H599734827\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Competing risks of cardiovascular and end-stage renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT OF CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general management of the patient with chronic kidney disease involves the following issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of reversible causes of renal dysfunction",
"     </li>",
"     <li>",
"      Preventing or slowing the progression of renal disease",
"     </li>",
"     <li>",
"      Treatment of the complications of renal dysfunction",
"     </li>",
"     <li>",
"      Identification and adequate preparation of the patient in whom renal replacement therapy will be required",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reversible causes of renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to exacerbation of their original renal disease, patients with chronic renal disease with a recent decrease in renal function may be suffering from an underlying reversible process, which if identified and corrected may result in the recovery of function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Decreased renal perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemia (such as vomiting, diarrhea, diuretic use, bleeding), hypotension (due to myocardial dysfunction or pericardial disease), infection (such as sepsis), and the administration of drugs which lower the GFR (such as nonsteroidal antiinflammatory drugs [NSAIDs] and ACE inhibitors) are common causes of potentially reversible declines in renal function.",
"   </p>",
"   <p>",
"    The normal response to renal hypoperfusion is to lower the urine sodium concentration (less than 25",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    and the fractional excretion of sodium (less than 1 percent in patients with advanced renal failure) to very low levels. However, the superimposition of a prerenal process among patients with chronic kidney disease may not result in the expected low values since the tubules in the diseased kidney are unable to reabsorb sodium so efficiently. As a result, hypovolemia in these patients should be diagnosed by the history and physical examination, including the presence of relative hypotension, a low jugular venous pressure, and poor skin turgor. In this setting, a judicious trial of fluid repletion may result in the return of renal function to the previous baseline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Administration of nephrotoxic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of drugs or diagnostic agents that adversely affect renal function are a frequent cause of worsening renal function. Among patients with chronic kidney disease, common offenders include aminoglycoside antibiotics (particularly with unadjusted doses), nonsteroidal antiinflammatory drugs, and radiographic contrast material, particularly in diabetics. The administration of such drugs should therefore be avoided or used with caution in patients with underlying chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain drugs also interfere with either creatinine secretion or the assay used to measure the serum creatinine. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    . In these settings, there will be no change in GFR; the clinical clue that this has occurred is the absence of a concurrent elevation in the blood urea nitrogen (BUN). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41875?source=see_link\">",
"     \"Drugs that elevate the serum creatinine concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Urinary tract obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract obstruction should always be considered in the patient with unexplained worsening renal function although, in the absence of prostatic disease, it is much less common than decreased renal perfusion. Patients with slowly developing obstruction typically have no changes in the urinalysis, no symptoms referable to the kidney, and initially maintain their urine output. Given this lack of clinical clues, renal ultrasonography is often performed to exclude urinary tract obstruction in patients with an unexplained elevation in the serum creatinine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Slowing the rate of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in experimental animals and humans suggest that progression in chronic kidney disease may be due at least in part to secondary factors that are unrelated to the activity of the initial disease. The major factors are thought to be intraglomerular hypertension and glomerular hypertrophy (which are primarily responsible for the adaptive hyperfiltration described above), leading to glomerular scarring (glomerulosclerosis). Additional causes may include hyperlipidemia, metabolic acidosis, and tubulointerstitial disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major histologic manifestation of hemodynamically-mediated renal injury is secondary focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, proteinuria typically occurs in patients with progressive chronic kidney disease, even in primary tubulointerstitial diseases such as reflux nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18078125\">",
"    <span class=\"h3\">",
"     Principal targets for renal protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy to slow the rate of progression in patients with chronic kidney disease (CKD), independent of treatment of the underlying disease, is centered on attaining the blood pressure goal and, in patients with proteinuric disease, attaining the proteinuria goal. Blood pressure goals for nondiabetic and diabetic patients are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link&amp;anchor=H34#H34\">",
"     \"Treatment of diabetic nephropathy\", section on 'Therapeutic goals'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to blood pressure control, specific goals related to a reduction in urinary protein excretion have been formulated to slow the rate of progression of proteinuric CKD. Proteinuria goals and the use of angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) agents in patients with proteinuric CKD are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Choice of antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to their renoprotective effects in proteinuric CKD, angiotensin inhibitors do",
"    <strong>",
"     not",
"    </strong>",
"    appear to be more beneficial than other antihypertensive agents in patients with nonproteinuric CKD. Recommendations for antihypertensive treatment of patients with nonproteinuric CKD are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H2001798#H2001798\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Sequence of antihypertensive therapy in nonproteinuric CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When used in patients with CKD, common side effects of angiotensin inhibition include a mild to moderate reduction in glomerular filtration rate, which occurs soon after the initiation of therapy or an increase in dose and hyperkalemia, which can occur either soon after the initiation of therapy or later if the patient has progressive CKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18078336\">",
"    <span class=\"h3\">",
"     Other targets for renal protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapeutic modalities also may offer some renal protection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protein restriction &minus; Protein restriction may slow the progression of CKD although the optimal level of protein intake has not been determined. This issue is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=see_link\">",
"       \"Protein restriction and progression of chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Statin therapy &minus; Both hyperlipidemia and metabolic acidosis should be treated, in part because there is some evidence that they may enhance the rate of progression of the renal disease (see below). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link\">",
"       \"Statins and chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking cessation &minus; Smoking stoppage is associated with a slower rate of progression of CKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/12\">",
"       12",
"      </a>",
"      ]. In an increasing number of studies, smoking also appears to correlate with an enhanced risk of developing kidney disease (primarily nephrosclerosis) as well as increasing the rate of progression among those with existing CKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of the complications of renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of disorders may develop as a consequence of the loss of renal function. These include disorders of fluid and electrolyte balance, such as volume overload, hyperkalemia, metabolic acidosis, and hyperphosphatemia, as well as abnormalities related to hormonal or systemic dysfunction, such as anorexia, nausea, vomiting, fatigue, hypertension, anemia, malnutrition, hyperlipidemia, and bone disease. Attention needs to be paid to all of these issues.",
"   </p>",
"   <p>",
"    One recommended diet, including suggestions for protein, fat, mineral, water, and vitamin intake, is presented in tables 1 and 2 (",
"    <a class=\"graphic graphic_table graphicRef71336 \" href=\"mobipreview.htm?9/56/10125\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73623 \" href=\"mobipreview.htm?25/50/26412\">",
"     table 4",
"    </a>",
"    ). This should be modified based upon the needs of the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Volume overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium and intravascular volume balance are usually maintained via homeostatic mechanisms until the GFR falls below 10 to 15",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    However, the patient with mild to moderate chronic kidney disease, despite being in relative volume balance, is less able to respond to rapid infusions of sodium and is therefore prone to fluid overload.",
"   </p>",
"   <p>",
"    Patients with chronic kidney disease and volume overload generally respond to the combination of dietary sodium restriction and diuretic therapy, usually with a loop diuretic given daily. Some investigators have also claimed that limiting sodium intake may also help decrease progression of chronic kidney disease by lowering intraglomerular pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/14\">",
"     14",
"    </a>",
"    ]. We agree with the 2012 KDIGO guidelines that, among all adults with CKD, sodium intake should be restricted to &lt;2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    unless contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=see_link\">",
"     \"Loop diuretics: Maximum effective dose and major side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"     \"Treatment of refractory edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to maintain potassium excretion at near normal levels is generally maintained in patients with renal disease as long as both aldosterone secretion and distal flow are maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Thus, hyperkalemia generally develops in the patient who is oliguric or who has an additional problem such as a high potassium diet, increased tissue breakdown, or hypoaldosteronism (due in some cases to the administration of an ACE inhibitor or ARB) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/17\">",
"     17",
"    </a>",
"    ]. Impaired cell uptake of potassium also may contribute to the development of hyperkalemia in advanced chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperkalemia due to ACE inhibitor or ARB therapy is most likely to occur in patients in whom the serum potassium concentration is elevated or in the high normal range prior to therapy. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to treating hyperkalemia, there are several measures that can help prevent hyperkalemia in patients with chronic kidney disease. These include ingestion of a low potassium diet (eg, less than 40 to 70",
"    <span class=\"nowrap\">",
"     mEq/day",
"    </span>",
"    [1500 to 2700",
"    <span class=\"nowrap\">",
"     mg/day])",
"    </span>",
"    and avoiding, if possible, the use of drugs that raise the serum potassium concentration such as nonsteroidal antiinflammatory drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/18\">",
"     18",
"    </a>",
"    ]. Nonselective beta-blockers make the postprandial rise in the serum potassium concentration but do not produce persistent hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Beta blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42640?source=see_link\">",
"     \"Patient information: Low potassium diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increasing tendency to retain hydrogen ions among patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. This can lead to a progressive metabolic acidosis with the serum bicarbonate concentration tending to stabilize between 12 and 20",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    and rarely falling below 10",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. The treatment of metabolic acidosis in CKD patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\", section on 'Treatment of metabolic acidosis in CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tendency toward phosphate retention begins early in renal disease, due to the reduction in the filtered phosphate load. Although this problem is initially mild with hyperphosphatemia being a relatively late event, phosphate retention is intimately related to the common development of secondary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From the viewpoint of calcium and phosphate balance, the hypersecretion of parathyroid hormone (PTH) is initially appropriate, since PTH can correct both hyperphosphatemia and hypocalcemia. As a result, phosphate balance and a normal serum phosphate concentration are generally maintained in patients with a GFR of greater than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/23\">",
"     23",
"    </a>",
"    ]. The price paid is secondary hyperparathyroidism and the development of renal osteodystrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dietary phosphate restriction and oral phosphate binders may limit the development of secondary hyperparathyroidism in patients with chronic kidney disease. Our approach, including the choice of phosphate binder is discussed elsewhere (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased intake of calcium may enhance coronary arterial calcification in this setting. This is thought by some to be associated with the development of coronary atherosclerosis, and may be related to the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consequences of elevated serum phosphorus, calcium, and parathyroid hormone levels. Detailed discussions of these issues, including specific",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .) The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for bone metabolism and disease in CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Renal osteodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in mineral metabolism and bone structure are an almost universal finding with progressive chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/24\">",
"     24",
"    </a>",
"    ]. The principal types of renal bone disease include osteitis fibrosa, osteomalacia, and adynamic bone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteitis fibrosa results from secondary hyperparathyroidism. Although an exact relationship is unclear, parathyroid hormone levels appear to increase when renal function decreases beyond a certain threshold value, with evidence suggesting that hormone levels begin to rise when the creatinine clearance is less than 40 to 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To help guide preventive measures, parathyroid hormone levels should therefore be assessed among such patients, as hormonal abnormalities are one of the earliest markers of abnormal bone mineral metabolism with progressive chronic kidney disease. Prevention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of osteitis fibrosis in patients with predialysis chronic kidney disease are primarily based upon dietary phosphate restriction, the administration of oral phosphate binders, and the administration of calcitriol (or vitamin D analogs) to directly suppress the secretion of parathyroid hormone.",
"   </p>",
"   <p>",
"    Calcitriol (1,25-dihydroxyvitamin D), the most active metabolite of vitamin D, is principally synthesized in the kidney. Circulating calcitriol levels begin to fall when the GFR is less than 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and are typically markedly reduced in subjects with end-stage renal disease. In addition to the loss of functioning renal mass, calcitriol production is also reduced by phosphate retention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcimimetics are agents that allosterically increase the sensitivity of the calcium-sensing receptor in the parathyroid gland to calcium. The calcium-sensing receptor is the principal factor regulating parathyroid gland parathyroid hormone secretion and hyperplasia. The separate target offers the potential to suppress parathyroid hormone secretion by mechanisms complementary and potentially synergistic with vitamin D analogues that target the vitamin D receptor. Although not approved for patients with CKD not yet on dialysis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    , the only currently available calcimimetic, is an emerging option in the treatment of secondary hyperparathyroidism in predialysis patients with CKD.",
"   </p>",
"   <p>",
"    Target serum levels for PTH as well as the approach to the management of this issue are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is present in approximately 80 to 85 percent of patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/27\">",
"     27",
"    </a>",
"    ]. Treating hypertension can both slow the progression of proteinuric CKD and reduce the rate of cardiovascular complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Blood pressure control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The desired degree of blood pressure control can usually be safely achieved with combined therapy which usually begins with an ACE inhibitor or angiotensin II receptor blocker (also given to slow disease progression as noted above) and a diuretic. Issues surrounding the treatment of hypertension among patients with diabetic nephropathy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Volume expansion, often in the absence of overt edema, contributes to the elevation in blood pressure in most forms of chronic kidney disease. As a result, before other medications are added, the dose of diuretics should be increased until the blood pressure is normalized or the patient has attained \"dry weight\" which, in the presence of persistent hypertension, is defined as the weight at which further fluid loss will lead either to symptoms (fatigue, orthostatic hypotension) or to decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the BUN and plasma creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A loop diuretic is recommended for the treatment of hypertension and edema in patients with chronic kidney disease. The thiazide diuretics in conventional dosage become less effective as monotherapy when the estimated GFR falls below 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2. They do, however, produce an additive effect when administered with a loop diuretic for refractory edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"     \"Treatment of refractory edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal blood pressure in hypertensive patients with chronic kidney disease is uncertain. The rate of loss of GFR appears to be more rapid when the mean arterial pressure remains at or above 100 mmHg (which reflects a diastolic pressure of 80 to 85 mmHg in the absence of systolic hypertension). To slow progression of chronic kidney disease, the optimal blood pressure depends in part on the degree of proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H12989801#H12989801\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goals depend upon protein excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our recommendations for blood pressure goals in patients with proteinuric CKD are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Slowing the rate of progression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our recommendations for blood pressure goals in patients with nonproteinuric CKD are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H12989801#H12989801\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goals depend upon protein excretion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H2001798#H2001798\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Sequence of antihypertensive therapy in nonproteinuric CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of chronic kidney disease is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney (a presumed reflection of the reduction in functioning renal mass), and to shortened red cell survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/28\">",
"     28",
"    </a>",
"    ]. Anemia is a common feature in many patients with chronic kidney disease who do not yet require dialysis, with anemia becoming increasingly common as glomerular filtration rates (GFRs) decline below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], particularly among diabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/31\">",
"     31",
"    </a>",
"    ]. As an example, based upon over 15,000 participants in the NHANES survey, the prevalence of anemia (Hbg &lt;12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in men and &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in women) increased from 1 percent at an eGFR of 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 to 9 percent at an eGFR of 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 and to 33 to 67 percent at an eGFR of 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2012 KDIGO guidelines suggest that, among patients who do not have anemia, the Hgb concentration should be checked when it is clinically indicated and at least yearly among all patients with stage 3 CKD (ie, estimated GFR 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2), at least every six months among patients with stage 4 to 5 CKD (ie, estimated GFR &le;29",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2), and at least every three months among patients who are on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/8,32\">",
"     8,32",
"    </a>",
"    ]. Among patients who are known to have anemia and are not treated with erythropoietin stimulating agents (ESAs), Hgb should be checked when it is clinically indicated, and at least every three months among patients with stage 3 to 5 (ie, estimated GFR &le;59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) who are not on hemodialysis (including patients who are on peritoneal dialysis); patients on hemodialysis should be monitored monthly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5594?source=see_link&amp;anchor=H27258970#H27258970\">",
"     \"Definition and staging of chronic kidney disease\", section on 'Staging of CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As stated in the 2012 KDIGO guidelines, the evaluation of anemia in those with CKD should begin when the Hgb level is less than 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in females, and Hgb levels of less than 13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in adult males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/8,32\">",
"     8,32",
"    </a>",
"    ] . These values are consistent with the World Health Organization (WHO) definition of anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/33\">",
"     33",
"    </a>",
"    ]. If untreated, the hematocrit of patients with advanced chronic kidney disease normally stabilizes at approximately 25 percent in the absence of bleeding or hemolysis.",
"   </p>",
"   <p>",
"    The anemia observed with chronic kidney disease is largely diagnosed by excluding non-renal causes of anemia in the patient with a suitably decreased GFR. The evaluation of patients should therefore include red blood cell indices, absolute reticulocyte count, serum iron, total iron binding capacity, percent transferrin saturation, serum ferritin, white blood cell count and differential, platelet count, B12 and folate concentrations, and testing for blood in stool. The content of hemoglobin in reticulocytes can also be assessed. This work-up should be performed prior to administering ESA therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluating the adequacy of iron stores in patients with CKD, and issues relating to iron therapy in such patients are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28005?source=see_link\">",
"     \"Diagnosis of iron deficiency in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although primarily used in patients with end-stage renal disease, erythropoietin stimulating agents (ESAs), such as erythropoietin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    , also correct the anemia in those with chronic kidney disease who do not yet require dialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of ESAs for the treatment of anemia in patients with CKD, including the 2012 KDIGO guideline recommendations, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal lipid metabolism is common in patients with renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/34\">",
"     34",
"    </a>",
"    ]. The primary finding in chronic kidney disease is hypertriglyceridemia with the total cholesterol concentration usually being normal (perhaps due in part to malnutrition in some patients). Patients with chronic kidney disease should be assessed for dyslipidemia, including a total cholesterol, LDL, HDL, and triglycerides. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for managing dyslipidemias in CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Among patients with CKD, the degree of hypertriglyceridemia that occurs may not be sufficient to significantly increase coronary risk, but other changes have been found that might contribute to the accelerated atherosclerosis commonly seen in end-stage renal disease. First, dietary modification may be helpful for the hypertriglyceridemia. Drug therapy in patients without renal failure may be beneficial in selected patients with isolated marked hypertriglyceridemia (serum triglycerides &ge;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&ge;5.65",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    who have proven coronary disease, a strong family history of CHD, or multiple coexisting cardiac risk factors. Whether this approach is beneficial in patients with renal failure is not known, but it should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link&amp;anchor=H723637365#H723637365\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Mild to moderate hypertriglyceridemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the patient with hypercholesterolemia, a statin can effectively and safely lower the plasma cholesterol concentration to or near acceptable levels. A related issue is the goal LDL-cholesterol level. Given evidence that mild to moderate degrees of chronic kidney disease are associated with an adverse cardiovascular prognosis, chronic kidney disease is considered a coronary heart disease equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal LDL-cholesterol is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link&amp;anchor=H339500#H339500\">",
"     \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\", section on 'Statin therapy versus LDL goals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data suggest that lipid lowering may have an additional benefit in patients with chronic kidney disease, which is slowing the rate of progression of the underlying renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H11#H11\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Hyperlipidemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link\">",
"     \"Statins and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant abnormalities in sexual and reproductive function are frequently observed in patients with advanced renal disease. As an example, over 50 percent of uremic men complain of symptoms that include erectile dysfunction, decreased libido, and marked declines in the frequency of intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/36\">",
"     36",
"    </a>",
"    ]; in addition, disturbances in menstruation and fertility are commonly encountered in women with chronic kidney disease, usually leading to amenorrhea by the time the patient reaches end-stage renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36484?source=see_link\">",
"     \"Reproductive and sexual dysfunction in uremic women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20951?source=see_link\">",
"     \"Sexual dysfunction in uremic men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important clinical implication of these abnormalities is that pregnancy which is carried to term is uncommon in women with a plasma creatinine concentration of 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (265",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment of complications of ESRD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient has reached the stage of near end-stage renal disease (GFR less than 15",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    signs and symptoms related to uremia begin to occur, such as malnutrition, anorexia, nausea, vomiting, fatigue, sexual dysfunction, platelet dysfunction, pericarditis, and neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition is common in patients with advanced chronic renal disease because of a lower food intake (principally due to anorexia), decreased intestinal absorption and digestion, and metabolic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Among participants &ge;60 years of age in the United States Third National Health and Nutrition Examination Survey (NHANES), a GFR &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    was independently associated with malnutrition (odds ratio of 3.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/39\">",
"     39",
"    </a>",
"    ]. Many additional studies have shown a strong correlation between malnutrition and death in maintenance dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4616?source=see_link\">",
"     \"Indications for initiation of dialysis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is therefore desirable to monitor the nutritional status of patients with chronic kidney disease. A low plasma concentration of albumin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    creatinine (which varies with muscle mass as well as GFR) may be indicative of malnutrition.",
"   </p>",
"   <p>",
"    To best assess nutritional status, the serum albumin concentration and body weight should be measured serially; these should be measured approximately every one to three months for those with estimated GFRs &lt;20",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and more frequently if necessary for those with GFRs &le;15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The desire to maintain adequate nutrition among patients with chronic renal failure clearly competes with attempts to slow the progression of renal dysfunction with the use of a low protein diet. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=see_link&amp;anchor=H6#H6\">",
"     \"Protein restriction and progression of chronic kidney disease\", section on 'Protein restriction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, the diet of most patients with chronic kidney disease should provide approximately 30 to 35",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/42\">",
"     42",
"    </a>",
"    ]. One recommended diet, including suggestions for protein, fat, mineral, water, and vitamin intake, is presented in the following tables (",
"    <a class=\"graphic graphic_table graphicRef71336 \" href=\"mobipreview.htm?9/56/10125\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73623 \" href=\"mobipreview.htm?25/50/26412\">",
"     table 4",
"    </a>",
"    ). The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for nutrition in CRF, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Uremic bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased tendency to bleeding is present in both acute and chronic kidney disease. This appears to correlate most closely with prolongation of the bleeding time, due primarily to impaired platelet function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No specific therapy is required in asymptomatic patients. However, correction of the platelet dysfunction is desirable in patients who are actively bleeding or who are about to undergo a surgical or invasive procedure (such as a renal biopsy). A number of different modalities can be used in this setting, including the correction of anemia, the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP), cryoprecipitate, estrogen, and the initiation of dialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in management have decreased the incidence of pericarditis in patients with chronic kidney disease, but this problem is still associated with significant morbidity and occasional mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6533?source=see_link\">",
"     \"Pericarditis in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever, pleuritic chest pain, and a pericardial friction rub are the major presentations of uremic pericarditis. One relatively characteristic feature of uremic pericarditis is that the electrocardiogram does not usually show the typical diffuse ST and T wave elevation, presumably because this is a metabolic pericarditis and epicardial injury is uncommon. Thus, the finding of these abnormalities suggests some other cause for the pericarditis. The occurrence of pericarditis in a patient with mild to moderate chronic kidney disease is another clue that the renal disease is probably not responsible.",
"   </p>",
"   <p>",
"    The development of otherwise unexplained pericarditis in a patient with advanced renal failure is an indication to institute dialysis (providing there is no circulatory compromise or evidence of impending tamponade) (see below). Most patients with uremic pericarditis respond rapidly to dialysis with resolution of chest pain as well as a decrease in the size of the pericardial effusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6533?source=see_link\">",
"     \"Pericarditis in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Uremic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of the central and peripheral nervous system, including encephalopathy (impaired mental status progressing if untreated to seizures and coma), polyneuropathy, and mononeuropathy are important complications of end-stage renal disease. They have become much less common because of the current tendency to earlier initiation of dialysis.",
"   </p>",
"   <p>",
"    Sensory dysfunctions, characterized by the restless leg or burning feet syndromes, are frequent presentations of uremic neuropathy. These complications are usually absolute indications for the initiation of dialysis. The extent of recovery from uremic neuropathy is directly related to the degree and extent of dysfunction prior to the initiation of dialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14773?source=see_link\">",
"     \"Uremic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Thyroid dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney normally plays an important role in the metabolism, degradation, and excretion of several thyroid hormones. It is not surprising therefore that impairment in kidney function leads to disturbed thyroid physiology. However, the overlap in symptomatology between the uremic syndrome and hypothyroidism requires a cautious interpretation of the tests of thyroid function.",
"   </p>",
"   <p>",
"    It is usually possible in the individual patient with chronic kidney disease to assess thyroid status accurately by physical diagnosis and thyroid function testing. The disturbances that can occur include low serum free and total T3 concentrations and normal reverse T3 and free T4 concentrations. The serum thyrotropin (TSH) concentration is normal and most patients are euthyroid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2453?source=see_link\">",
"     \"Thyroid function in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H134901364\">",
"    <span class=\"h1\">",
"     INFECTION AND VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CKD are at increased risk for infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. The risk of bacterial infection (particularly pulmonary and genitourinary) increases with the decline in kidney function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. In one study, compared with an estimated GFR greater than or equal to 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2, estimated GFRs between 60 to 89, 45 to 59, and 15 to 44",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 were associated with 16, 37, and 64 percent greater risks of all-cause infection related hospitalization, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful attention should be paid to preventive measures such as influenza and pneumococcal immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the following 2012 KDIGO guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults with all stages of CKD should be offered annual vaccination with influenza virus, unless contraindicated.",
"     </li>",
"     <li>",
"      Adults with CKD stages 4 and 5 should be vaccinated with the polyvalent pneumococcal vaccine, unless contraindicated. Patients who have received pneumococcal vaccination should be offered revaccination within five years.",
"     </li>",
"     <li>",
"      Adults with stage 4 and 5 CKD who are at high risk of progression of CKD should be immunized against hepatitis B and the response confirmed by immunologic testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PREPARATION FOR AND INITIATION OF RENAL REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to identify patients who may eventually require renal replacement therapy since adequate preparation can decrease morbidity and perhaps mortality. Early identification enables dialysis to be initiated at the optimal time with a functioning chronic access and may also permit the recruitment and evaluation of family members for the placement of a renal allograft prior to the need for dialysis. In addition, the ability of the individual to psychologically accept the requirement of life-long renal replacement therapy is often diminished if inadequate time has elapsed between the time of recognition of end-stage renal disease and the initiation of dialysis.",
"   </p>",
"   <p>",
"    Chronic kidney disease progresses at a variable rate due to differences in the clinical course of the underlying diseases (particularly between individuals) and the recognition that the natural history of progressive renal disease can be altered by various therapeutic interventions, particularly strict blood pressure control with an ACE inhibitor or ARB. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Slowing the rate of progression'",
"    </a>",
"    above.) As a result, exactly if and when a patient may require dialysis or renal transplantation is unclear. In addition, some patients refuse renal replacement therapy until the onset of absolute indications, while others desire early initiation to avoid the complications of severe chronic kidney disease, such as malnutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Referral to nephrologists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CKD should be referred to a nephrologist early in the course of their disease, preferably before the plasma creatinine concentration exceeds 1.2 (106",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in women and men, respectively, or the eGFR is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. These subspecialists are trained to help counsel the patient in choosing the optimal renal replacement therapy and to manage the many issues associated with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/49\">",
"     49",
"    </a>",
"    ]. Lower costs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased morbidity and mortality may be associated with early referral and care by subspecialists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/50-60\">",
"     50-60",
"    </a>",
"    ]. Reasons for later referral may include disease specific factors, patient and physician dependent causes, and health care system related factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25640?source=see_link\">",
"     \"Late referral to nephrologists of patients with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are guidelines that advocate early screening for patients at risk of chronic kidney disease. The",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines for CKD recommend that all individuals should be assessed, as part of routine health examinations, to determine whether they are at increased risk for developing CKD. The detection of patients with early disease may also facilitate proper care and early referral to nephrologists. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/32/521?source=see_link\">",
"     \"Epidemiology of chronic kidney disease\"",
"    </a>",
"    .) The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    An equally important component of early identification is institution of renoprotective therapy (eg, ACE inhibitor, angiotensin II receptor blocker, and rigorous blood pressure control) as early as possible after identifying the presence of progressive chronic kidney disease. Protective therapy has the greatest impact if it is initiated before the plasma creatinine concentration exceeds 1.2 (106",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in women and men, respectively, or the eGFR is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2. At this point, most patients have already lost more than one-half of their GFR. Waiting until the disease progresses further diminishes the likelihood of a successful response but still should be attempted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Slowing the rate of progression'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Choice of renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it is determined that renal replacement therapy will eventually be required, the patient should be counseled to consider the advantages and disadvantages of hemodialysis (in-center or at home), peritoneal dialysis (continuous or intermittent modalities), and renal transplantation (living or deceased donor) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/62\">",
"     62",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that patients with a GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 should be educated concerning these issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kidney transplantation is the treatment of choice for end-stage renal disease. A successful kidney transplant improves the quality of life and reduces the mortality risk for most patients, when compared with maintenance dialysis. To facilitate early transplantation, a 2008",
"    <span class=\"nowrap\">",
"     NKF/KDOQI",
"    </span>",
"    conference suggested early education and referral to a transplantation center plus the identification of potential living donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all patients are appropriate candidates for a kidney allograft because of absolute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    relative contraindications to this procedure or the subsequent required medications. Referral to a transplant program should occur once renal replacement therapy is thought to be required within the next year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Living donor transplants, if available, have the additional advantage of being performed with minimal delay, thereby permitting preemptive transplantation (transplantation prior to dialysis). Such patients appear to have improved graft survival compared to those who undergo a period of dialysis before transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=see_link\">",
"     \"Dialysis issues prior to and after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these individuals and for those who are suitable transplant recipients but must wait for an available kidney, the choice between hemodialysis or peritoneal dialysis is influenced by a number of considerations such as availability, convenience, comorbid conditions, home situation, age, gender, and the ability to tolerate volume shifts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34312?source=see_link\">",
"     \"Dialysis modality and patient outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31286?source=see_link\">",
"     \"Choosing a modality for chronic peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10614?source=see_link\">",
"     \"Dialysis in diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, the universal availability of renal replacement therapy forces the nephrologist to consider its application in every patient in whom it might be indicated. However, the patient, particularly the elderly and terminally ill, may refuse dialysis, a choice which is assuming more prominence as patients and physicians grapple with the increasing use of advance directives, and the laudable goals of death with dignity and life with quality. Nevertheless, not all nephrologists are willing to recommend no treatment, especially when dialysis facilities are available with no need to ration therapy. These issues can be a source of conflict among physicians, patients, and their families. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Preparation for hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis requires a stable access to the bloodstream to permit dialysis to be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/7/115?source=see_link\">",
"     \"Overview of the hemodialysis apparatus\"",
"    </a>",
"    .) The access should generally be placed in the nondominant upper extremity, because of the increased risk of infection and more severe consequences of arterial steal syndrome with lower extremity grafts. Venipuncture should therefore be restricted to the arm not chosen for eventual access placement so that the veins in the other arm will be preserved.",
"   </p>",
"   <p>",
"    There are three major types of vascular access for maintenance hemodialysis: primary arteriovenous (AV) fistulas; synthetic arteriovenous fistulas (AV grafts); and double-lumen, cuffed tunneled catheters. To facilitate placement of a permanent vascular access, the 2008 Society for Vascular Surgery guidelines recommend that patients be referred to an access surgeon when the patient has late stage 4 CKD, defined by an estimated GFR of less than 20 to 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Primary AV fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary AV fistulas are the preferred form of vascular access given their significantly higher long-term patency rates and lower rate of complications. Since a primary AV fistula requires months to mature and is the access of choice, patients should be referred for surgery to attempt access construction when it is estimated that the patient is within one year of the anticipated need for dialysis as manifested by a GFR less than 25",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    a plasma creatinine concentration greater than 4",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (354",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    or a rapid rate of progression. The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that a fistula be placed at least six months prior to the anticipated start of hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary AV fistulas are typically constructed with an end-to-side vein-to-artery anastomosis of the cephalic vein and the radial artery. These fistulas have good long-term patency and infrequently develop infectious complications. A well constructed radial cephalic fistula that functions for the first six months can be expected to function for up to 20 years.",
"   </p>",
"   <p>",
"    The evaluation of non-maturing AV fistulas may require an assessment with procedures that involve the administration of iodinated radiocontrast agents, thereby possibly resulting in radiocontrast-induced nephropathy and required early dialysis. In one study of 65 endovascular procedures among 34 patients with stage 4 CKD and nonmaturing AV fistulas, contrast-induced nephropathy (25 percent increase in serum creatinine concentration) occurred in only 5 percent of patients at one week post-procedure and no one required acute dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/68\">",
"     68",
"    </a>",
"    ]. The mean contrast volume was small (mean of 7.8 mL per procedure).",
"   </p>",
"   <p>",
"    The administration of gadolinium during magnetic resonance imaging has been linked to an often severe disease called nephrogenic systemic fibrosis among patients with moderate to severe renal disease, particularly those requiring dialysis. As a result, it is recommended that gadolinium-based imaging be avoided, if possible, in patients with an eGFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    There is no consensus among experts concerning the decision to administer gadolinium among patients with an eGFR between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Synthetic AV access (bridge grafts)",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV fistulas constructed with synthetic material, most commonly polytetrafluoroethylene (PTFE), provide excellent vascular access in patients who fail endogenous AV fistula placement. PTFE has good surgical handling characteristics, and grafts of this material usually mature in two weeks. Synthetic grafts have a higher long-term complication rate (eg, infection, thrombosis) than primary fistulas. The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that a synthetic graft be placed at least three to six weeks prior to the anticipated start of hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Cuffed tunneled catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;These central venous catheters, which can be used immediately after placement, are primarily used as intermediate-duration vascular access to allow maturation of endogenous fistulas. They can also provide acceptable long-term access in patients who have exhausted all available sites. Nevertheless, these central venous catheters are inferior to AV access as long-term access, since they provide lower flows and have higher rates of infection and other complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Preparation for peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis catheters, which are placed into the abdominal cavity, can be used immediately after placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/69\">",
"     69",
"    </a>",
"    ]. However, to minimize the risk of fluid leak, it is preferable to wait at least 10 to 14 days before beginning dialysis. If dialysis is required less than 10 days following catheter placement, small volume exchanges performed in the recumbent position can be performed with little risk of leak. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6136?source=see_link&amp;anchor=H16#H16\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\", section on 'Postoperative catheter care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Preparation for renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparation for renal transplantation, which principally involves evaluation of the potential renal transplant recipient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the living donor, is discussed in detail separately. Referral of patients with CKD to a transplant center should occur when the GFR decreases to less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or, among diabetics, when the GFR is between 30 to 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31925?source=see_link\">",
"     \"Living unrelated donors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Indications for renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of clinical indications to initiate dialysis in patients with chronic kidney disease (CKD). These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/63,71,72\">",
"     63,71,72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pericarditis or pleuritis (urgent indication)",
"     </li>",
"     <li>",
"      Progressive uremic encephalopathy or neuropathy, with signs such as confusion, asterixis, myoclonus, wrist or foot drop, or, in severe, cases, seizures (urgent indication)",
"     </li>",
"     <li>",
"      A clinically significant bleeding diathesis attributable to uremia (urgent indication)",
"     </li>",
"     <li>",
"      Fluid overload refractory to diuretics",
"     </li>",
"     <li>",
"      Hypertension poorly responsive to antihypertensive medications",
"     </li>",
"     <li>",
"      Persistent metabolic disturbances that are refractory to medical therapy. These include hyperkalemia, metabolic acidosis, hypercalcemia, hypocalcemia, and hyperphosphatemia.",
"     </li>",
"     <li>",
"      Persistent nausea and vomiting",
"     </li>",
"     <li>",
"      Evidence of malnutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative indications for the initiation of dialysis include decreased attentiveness and cognitive tasking, depression, persistent pruritus or the restless leg syndrome.",
"   </p>",
"   <p>",
"    We suggest that, among patients with progressive CKD, clinicians must be vigilant for the presence of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of uremia and patients should also be fully informed of any symptoms of uremia to be able to contact their physicians appropriately. Dialysis should be considered based upon clinical factors plus the estimated GFR. Dialysis should be initiated in the patient with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs due to uremia.",
"   </p>",
"   <p>",
"    Among asymptomatic patients with progressive CKD, the timing of initiation of dialysis is unclear and there is no specific threshold GFR level that has been established for the initiation of dialysis. To help avoid the onset of possible life-threatening complications of uremia, the initiation of dialysis should be considered in the asymptomatic patient with an extremely low GFR, such as an estimated GFR of approximately 8 to 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. However, some clinicians may choose to closely monitor (weekly) asymptomatic patients with progressive CKD even when the GFR is less than 8 to 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, with the initiation of dialysis upon the onset of uremic",
"    <span class=\"nowrap\">",
"     signs/symptoms.",
"    </span>",
"    Nevertheless, as noted in the IDEAL trial, the vast majority of patients are initiated on dialysis because of the onset of uremic symptoms at a GFR of approximately 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 or above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/73\">",
"     73",
"    </a>",
"    ]. All approaches require close followup, early nephrology referral, and adequate advance dialysis planning (including the presence of a functioning peritoneal or vascular access and referral for transplantation). A detailed discussion of the IDEAL trial and indications for dialysis in the patient with CKD can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4616?source=see_link\">",
"     \"Indications for initiation of dialysis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are some of the more recent National and International Guidelines for the initiation of dialysis, which were published before the results of the IDEAL trial were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2006 National Kidney Foundation Dialysis Outcomes Quality Initiative",
"      <span class=\"nowrap\">",
"       (K/DOQI)",
"      </span>",
"      for peritoneal dialysis and hemodialysis adequacy published guidelines concerning the initiation of dialysis among patients with renal insufficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/63,72\">",
"       63,72",
"      </a>",
"      ]. The work group suggested that the benefits and risks of initiating renal replacement therapy should be considered in patients with GFR less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (stage 5 chronic kidney disease). Initiation of dialysis prior to stage 5 chronic kidney disease may also be required in patients with certain characteristics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complications, such as declining health due to the loss of kidney function.",
"     </li>",
"     <li>",
"      The 2005 European Best Practice Guidelines for peritoneal dialysis suggest that dialysis be initiated before the GFR is less than 6",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2, with consideration of initiation when the GFR is approximately 8 to 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 KDIGO guidelines suggest that dialysis be initiated when there are signs or symptoms attributable to kidney failure (such as serositis, acid-base or electrolyte disorders not easily corrected medically, pruritus), an inability to control volume status or blood pressure, a progressive deterioration in nutritional status that is refractory to dietary interventions, or cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/35/37434/abstract/8\">",
"     8",
"    </a>",
"    ]. The 2012 KDIGO guidelines state that such signs and symptoms often but not invariably occur when the estimated GFR is between 5 and 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=see_link\">",
"       \"Patient information: Chronic kidney disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/43/16051?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/2/18467?source=see_link\">",
"       \"Patient information: Dialysis and diet (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/17/24850?source=see_link\">",
"       \"Patient information: Bone problems caused by kidney disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/62/9188?source=see_link\">",
"       \"Patient information: Medicines for chronic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=see_link\">",
"       \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=see_link\">",
"       \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/7/28799?source=see_link\">",
"       \"Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a significant number of general issues related to the management of patients with chronic kidney disease. These are discussed in the following sections of this topic review:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Natural history of chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history of renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definition and classification of chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Association of chronic kidney disease with cardiovascular disease, end-stage renal disease, infection, malignancy and mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Association with cardiovascular disease, end-stage renal disease, and mortality'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H134901364\">",
"       'Infection and vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of chronic kidney disease, which includes treatment of reversible causes of renal dysfunction, preventing or slowing the progression of renal disease, treatment of the complications of renal dysfunction, and the identification and adequate preparation of the patient in whom renal replacement therapy will be required. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General management of chronic kidney disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Preparation for and initiation of renal replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/1\">",
"      Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010; 362:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/2\">",
"      Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/3\">",
"      Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006; 69:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/4\">",
"      Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/5\">",
"      Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/6\">",
"      Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/7\">",
"      Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006; 17:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/8\">",
"      KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/9\">",
"      Snyder JJ, Collins AJ. Association of preventive health care with atherosclerotic heart disease and mortality in CKD. J Am Soc Nephrol 2009; 20:1614.",
"     </a>",
"    </li>",
"    <li>",
"     Schieppati, A, Pisoni, R, Remuzzi, G. Pathophysiology and management of chronic kidney disease. In: Primer on Kidney Diseases, Greenberg, A (Ed), Elsevier Saunders, Philadelphia, 2005, p. 444.",
"    </li>",
"    <li>",
"     Rennke, HG, Anderson, S, Brenner, BM. Structural and functional correlations in the progression of renal disease. In: Renal Pathology, Tisher, CC, Brenner, BM (Eds), Lippincott, Philadelphia, 1989, pp. 43-66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/12\">",
"      Orth SR. Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J Am Soc Nephrol 2004; 15 Suppl 1:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/13\">",
"      Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008; 3:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/14\">",
"      Weir MR, Fink JC. Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary. Am J Kidney Dis 2005; 45:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/15\">",
"      Gonick HC, Kleeman CR, Rubini ME, Maxwell MH. Functional impairment in chronic renal disease. 3. Studies of potassium excretion. Am J Med Sci 1971; 261:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/16\">",
"      Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant 2002; 17:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/17\">",
"      Gennari FJ, Segal AS. Hyperkalemia: An adaptive response in chronic renal insufficiency. Kidney Int 2002; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/18\">",
"      Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol 1995; 6:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/19\">",
"      Uribarri J, Douyon H, Oh MS. A re-evaluation of the urinary parameters of acid production and excretion in patients with chronic renal acidosis. Kidney Int 1995; 47:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/20\">",
"      Warnock DG. Uremic acidosis. Kidney Int 1988; 34:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/21\">",
"      Widmer B, Gerhardt RE, Harrington JT, Cohen JJ. Serum electrolyte and acid base composition. The influence of graded degrees of chronic renal failure. Arch Intern Med 1979; 139:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/22\">",
"      Wallia R, Greenberg A, Piraino B, et al. Serum electrolyte patterns in end-stage renal disease. Am J Kidney Dis 1986; 8:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/23\">",
"      Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/24\">",
"      Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/25\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/26\">",
"      Muntner P, Jones TM, Hyre AD, et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol 2009; 4:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/27\">",
"      Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996; 50:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/28\">",
"      Eschbach JW. Erythropoietin 1991--an overview. Am J Kidney Dis 1991; 18:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/29\">",
"      Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/30\">",
"      Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/31\">",
"      El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int 2005; 67:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/32\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia, de Benoist  B, McLea E, Egli I, Cogswell M.  (Eds), 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/34\">",
"      Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/35\">",
"      Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/36\">",
"      Procci WR, Goldstein DA, Adelstein J, Massry SG. Sexual dysfunction in the male patient with uremia: a reappraisal. Kidney Int 1981; 19:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/37\">",
"      Hou S. Pregnancy in women with chronic renal disease. N Engl J Med 1985; 312:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/38\">",
"      Kopple JD, Greene T, Chumlea WC, et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 2000; 57:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/39\">",
"      Garg AX, Blake PG, Clark WF, et al. Association between renal insufficiency and malnutrition in older adults: results from the NHANES III. Kidney Int 2001; 60:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/40\">",
"      Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003; 64:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/41\">",
"      Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Ahmed, K, Kopple, J. Nutritional management of renal disease. In: Primer on Kidney Diseases, Greenberg, A (Ed). Academic Press, San Diego, CA, 1994, p. 289.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/43\">",
"      James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/44\">",
"      Dalrymple LS, Katz R, Kestenbaum B, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/45\">",
"      Wu MY, Hsu YH, Su CL, et al. Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis 2012; 60:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/46\">",
"      Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006; 13:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/47\">",
"      Coresh J. CKD prognosis: beyond the traditional outcomes. Am J Kidney Dis 2009; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/48\">",
"      James MT, Laupland KB. Examining noncardiovascular morbidity in CKD: estimated GFR and the risk of infection. Am J Kidney Dis 2012; 59:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/49\">",
"      Pereira BJ. Optimization of pre-ESRD care: the key to improved dialysis outcomes. Kidney Int 2000; 57:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/50\">",
"      Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007; 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/51\">",
"      Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis 2001; 38:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/52\">",
"      Winkelmayer WC, Owen WF Jr, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol 2003; 14:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/53\">",
"      Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis 2003; 41:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/54\">",
"      Winkelmayer WC, Levin R, Avorn J. The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. Kidney Int 2003; 63:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/55\">",
"      Kessler M, Frimat L, Panescu V, Brian&ccedil;on S. Impact of nephrology referral on early and midterm outcomes in ESRD: EPid&eacute;miologie de l'Insuffisance REnale chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective, community-based study. Am J Kidney Dis 2003; 42:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/56\">",
"      Khan SS, Xue JL, Kazmi WH, et al. Does predialysis nephrology care influence patient survival after initiation of dialysis? Kidney Int 2005; 67:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/57\">",
"      Patwardhan MB, Samsa GP, Matchar DB, Haley WE. Advanced chronic kidney disease practice patterns among nephrologists and non-nephrologists: a database analysis. Clin J Am Soc Nephrol 2007; 2:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/58\">",
"      Chan MR, Dall AT, Fletcher KE, et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med 2007; 120:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/59\">",
"      Tseng CL, Kern EF, Miller DR, et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch Intern Med 2008; 168:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/60\">",
"      Chow KM, Szeto CC, Law MC, et al. Impact of early nephrology referral on mortality and hospitalization in peritoneal dialysis patients. Perit Dial Int 2008; 28:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/61\">",
"      Wauters JP, Lameire N, Davison A, Ritz E. Why patients with progressing kidney disease are referred late to the nephrologist: on causes and proposals for improvement. Nephrol Dial Transplant 2005; 20:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/62\">",
"      G&oacute;mez CG, Valido P, Celadilla O, et al. Validity of a standard information protocol provided to end-stage renal disease patients and its effect on treatment selection. Perit Dial Int 1999; 19:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/63\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/64\">",
"      Abecassis M, Bartlett ST, Collins AJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol 2008; 3:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/65\">",
"      Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/66\">",
"      Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/67\">",
"      Sidawy AN, Spergel LM, Besarab A, et al. The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. J Vasc Surg 2008; 48:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/68\">",
"      Kian K, Wyatt C, Schon D, et al. Safety of low-dose radiocontrast for interventional AV fistula salvage in stage 4 chronic kidney disease patients. Kidney Int 2006; 69:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/69\">",
"      Ghaffari A. Urgent-start peritoneal dialysis: a quality improvement report. Am J Kidney Dis 2012; 59:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/70\">",
"      Gaston RS, Basadonna G, Cosio FG, et al. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis 2004; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     Pendse, S, Singh, A, Zawada, E. Initiation of dialysis in Handbook of Dialysis, 4th ed, Daugirdas, JT, Blake, PG, Ing, TS (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/72\">",
"      K/DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy. Am J Kidney Dis 2006; 47(Suppl 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/73\">",
"      Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010; 363:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/35/37434/abstract/74\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7172 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37434=[""].join("\n");
var outline_f36_35_37434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY OF RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSOCIATION WITH CARDIOVASCULAR DISEASE, END-STAGE RENAL DISEASE, AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENERAL MANAGEMENT OF CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reversible causes of renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Decreased renal perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Administration of nephrotoxic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Urinary tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Slowing the rate of progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18078125\">",
"      - Principal targets for renal protection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18078336\">",
"      - Other targets for renal protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of the complications of renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Volume overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment of complications of ESRD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Uremic bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Uremic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H134901364\">",
"      INFECTION AND VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PREPARATION FOR AND INITIATION OF RENAL REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Referral to nephrologists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Choice of renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Preparation for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Primary AV fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Synthetic AV access (bridge grafts)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Cuffed tunneled catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Preparation for peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Preparation for renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Indications for renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7172|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/46/41701\" title=\"figure 1\">",
"      Relative risks of major complications of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/44/28360\" title=\"figure 2\">",
"      Relative risks of the main complications of CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7172|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/62/22509\" title=\"table 1\">",
"      Definition and criteria for CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/47/14076\" title=\"table 2\">",
"      Revised CKD classification based upon GFR and albuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/56/10125\" title=\"table 3\">",
"      Diet and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/50/26412\" title=\"table 4\">",
"      Vitamin intake in CKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31286?source=related_link\">",
"      Choosing a modality for chronic peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5594?source=related_link\">",
"      Definition and staging of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28005?source=related_link\">",
"      Diagnosis of iron deficiency in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10614?source=related_link\">",
"      Dialysis in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34312?source=related_link\">",
"      Dialysis modality and patient outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41875?source=related_link\">",
"      Drugs that elevate the serum creatinine concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4616?source=related_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25640?source=related_link\">",
"      Late referral to nephrologists of patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=related_link\">",
"      Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31925?source=related_link\">",
"      Living unrelated donors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=related_link\">",
"      Loop diuretics: Maximum effective dose and major side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/7/115?source=related_link\">",
"      Overview of the hemodialysis apparatus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/17/24850?source=related_link\">",
"      Patient information: Bone problems caused by kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/2/18467?source=related_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42640?source=related_link\">",
"      Patient information: Low potassium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/62/9188?source=related_link\">",
"      Patient information: Medicines for chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=related_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/7/28799?source=related_link\">",
"      Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6533?source=related_link\">",
"      Pericarditis in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6136?source=related_link\">",
"      Placement and maintenance of the peritoneal dialysis catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=related_link\">",
"      Protein restriction and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36484?source=related_link\">",
"      Reproductive and sexual dysfunction in uremic women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20951?source=related_link\">",
"      Sexual dysfunction in uremic men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2453?source=related_link\">",
"      Thyroid function in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14773?source=related_link\">",
"      Uremic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/24/37258?source=related_link\">",
"      Uremic toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_35_37435="PBL levels";
var content_f36_35_37435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patterns of peripheral blood lymphocyte levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Defective protein",
"      </td>",
"      <td class=\"subtitle1\">",
"       CD4",
"      </td>",
"      <td class=\"subtitle1\">",
"       CD8",
"      </td>",
"      <td class=\"subtitle1\">",
"       B",
"      </td>",
"      <td class=\"subtitle1\">",
"       NK",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RAG1/RAG2",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MHCII",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD3 delta",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL/&uarr;",
"      </td>",
"      <td>",
"       NL/&uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD3 gamma",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD3 epsilon",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD3 zeta",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;/NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       p56lck",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL/&uarr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ZAP-70",
"      </td>",
"      <td>",
"       NL/&uarr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       &darr;/NL",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37435=[""].join("\n");
var outline_f36_35_37435=null;
var title_f36_35_37436="Impact of medications and methylxanthines on stress testing";
var content_f36_35_37436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for withholding medications and methylxanthines when testing is performed for the diagnosis of coronary heart disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Considerations if withholding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta blockers",
"       </td>",
"       <td>",
"        Withhold for 48 hours",
"       </td>",
"       <td>",
"        Hypertension and arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers",
"       </td>",
"       <td>",
"        Withhold for 48 hours",
"       </td>",
"       <td>",
"        Hypertension and arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrates",
"       </td>",
"       <td>",
"        Withhold for 48 hours",
"       </td>",
"       <td>",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ACEI",
"       </td>",
"       <td>",
"        Continue",
"       </td>",
"       <td>",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ARB",
"       </td>",
"       <td>",
"        Continue",
"       </td>",
"       <td>",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"       <td>",
"        Continue as withholding not practical due to extended washout period",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L-Arginine",
"       </td>",
"       <td>",
"        Withhold prior to testing",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Statins",
"       </td>",
"       <td>",
"        Continue",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Methylxanthines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Caffeine containing foods and beverages",
"       </td>",
"       <td class=\"sublist_other\">",
"        Withhold for 12 hours prior to vasodilator stress testing",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aminophylline",
"       </td>",
"       <td class=\"sublist_other\">",
"        Withhold for 24 hours prior to vasodilator stress testing",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dipyridamole",
"       </td>",
"       <td class=\"sublist_other\">",
"        Withhold for 48 hours prior to vasodilator stress testing",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digoxin",
"       </td>",
"       <td>",
"        Continue as withholding not practical due to extended washout period",
"       </td>",
"       <td>",
"        Perform concomitant imaging as initial approach or if results felt to be falsely positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogen",
"       </td>",
"       <td>",
"        Continue as withholding not practical due to extended washout period",
"       </td>",
"       <td>",
"        Perform concomitant imaging as initial approach or if results felt to be falsely positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuretics",
"       </td>",
"       <td>",
"        Continue",
"       </td>",
"       <td>",
"        Replete hypokalemia prior to stress testing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37436=[""].join("\n");
var outline_f36_35_37436=null;
var title_f36_35_37437="Frequency of arrhythmia and ICD events in AVID";
var content_f36_35_37437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arrhythmic events in patients with an ICD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 541px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-term follow-up of the 449 patients assigned to an implantable cardioverter-defibrillator (ICD) in the AVID trial of secondary prevention of sudden cardiac death. Depicted is the cumulative percentage of patients over time with an arrhythmic event (arrhythmic death, sustained ventricular arrhythmia, or a shock or antitachycardia pacing from the ICD) (top panel) or an ICD shock (bottom panel). Among patients who had an event, approximately one-half occurred in the first few months and most by two years. However, some patients had an initial event after two years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Klein RC, Raitt MH, Wilkoff BL, Beckman KJ. J Cardiovasc Electrophysiol 2003; 14:940.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37437=[""].join("\n");
var outline_f36_35_37437=null;
var title_f36_35_37438="Plummer Vinson syndrome";
var content_f36_35_37438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barium swallow in a patient with Plummer Vinson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 234px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This barium swallow study obtained in a 53-year-old female with dysphagia and anemia demonstrates an upper esophageal web (black arrow) immediately above a tight stricture of the esophagus (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37438=[""].join("\n");
var outline_f36_35_37438=null;
var title_f36_35_37439="Metered dose inhaler PI";
var content_f36_35_37439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Metered dose inhaler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medicine is stored in the canister. When a person presses down on the top of the canister, the medicine travels through the dosing chamber and sprays out of the mouthpiece.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_35_37439=[""].join("\n");
var outline_f36_35_37439=null;
